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G protein biased signaling by non-catechol dopamine D1 
receptor agonists 
Abstract 
Dopamine is a catecholamine neurotransmitter with essential roles in voluntary 
movement, working memory, attention, and reward. Dopamine acts through five G protein 
coupled receptors with the D1 and D5 receptors (D1R) stimulating Gs/olf activation and increasing 
neuronal excitability. Deficits in D1R signaling are implicated in Parkinson’s disease motor deficits 
as well as cognitive deficits in schizophrenia and attention deficit hyperactivity disorder. For more 
than 40 years, academic and industry scientists have been searching for a drug-like D1R agonist, 
but this has remained elusive. The challenge in developing D1R selective agonists is that all 
previous agonists possess a common problematic chemical moiety, a catechol. Catechols are 
associated with poor oral bioavailability, poor brain penetration, and rapid metabolism in the 
serum. Very recently, the breakthrough discovery of the first non-catechol D1R selective agonists 
overcame the pitfalls associated with the catechols. Unexpectedly, the non-catechol agonists also 
selectively activate G protein signaling without engaging -arrestin indicating that they are G 
protein biased. The primary goals for this study were to characterize novel signaling by non-
catechol agonists and elucidate a mechanism of action for the G protein biased non-catechol 
agonists. First, the role of -arrestin in D1R agonist-induced endocytosis was established in 
HEK293 cells that had -arrestin1/2 knocked out by CRISPR/Cas9 genome editing. The knockout 
of -arrestin1/2 eliminated D1R agonist-induced endocytosis. -arrestin1/2 knockout significantly 
reduced D1R agonist-induced endocytosis in an ELISA assay that measures cell surface D1R. 
Furthermore, re-expressing either -arrestin1 or 2 rescued D1R endocytosis in confocal imaging 
and cell surface ELISA assays. Together, these results indicate that -arrestin1/2 are required for 
D1R agonist-induced endocytosis. Next, catechol and non-catechol D1R agonists were tested in 
 xi 
 
cAMP Glosensor and -arrestin Tango assays to investigate potential biased signaling. The 
unbiased catechol D1R full agonist SKF-81297 was used as the reference compound in all 
following studies. The non-catechol D1R agonists dose-dependently increased cAMP production 
in HEK293 cells similar to the full agonist SKF-81297 (Emax 100%), but did not engage -arrestin. 
Interestingly, one non-catechol agonist (PW441) robustly activated both cAMP (Emax = 92%, EC50 
= 4.4 nM) and also fully recruited -arrestin (Emax = 100%, EC50 = 100 nM). The catechol agonist 
A-77636 dose-dependently increased full cAMP production (Emax = 104%, EC50 = 3.1 nM) but was 
a super agonist for -arrestin recruitment (Emax = 130%, EC50 = 35 nM). To determine the effect 
of G protein biased agonists on D1R endocytosis, the catechol and non-catechol D1R agonists 
were tested in imaging and cell surface ELISA assays. The non-catechol G protein biased 
agonists all induced significantly less total D1R endocytosis than the catechol agonist SKF-81297. 
The pure G protein biased agonists PF-1119 and PW464 maximally induced 5% and 11% loss of 
cell surface D1R, respectively. In contrast, the catechol A-77636 maximally induced 47% loss of 
cell surface D1R and induced significantly more total endocytosis than SKF-81297. Moreover, the 
efficacy for -arrestin recruitment strongly correlates to the maximum receptor endocytosis in 
Spearman’s correlation analysis (r = 0.96, p<0.05). Collectively, this study demonstrates the 
essential role of -arrestin in D1R agonist-induced endocytosis and characterizes novel non-
catechol agonists. In addition, the discovery of the first balanced non-catechol D1R selective 
agonist adds a unique tool for future in vitro and in vivo studies. These results further elucidate a 
mechanism of action for the G protein biased non-catechol agonists in which agonist binding 
induces G protein activation without also inducing D1R endocytosis. These results provide 
insights into the molecular mechanism of the G protein biased non-catechol agonists. While the 
clinical efficacy of the non-catechol agonists is currently being explored, the mechanism of action 





1.1 Neuronal signaling and synaptic transmission 
Neurons are unique cells in our bodies that conduct information rapidly. This information 
is encoded by electrochemical signaling where electrical potential at axon terminals is rapidly 
converted into a chemical signal that bridges the gap between neurons. Synaptic signaling 
induces changes in membrane potential or metabotropic changes in the postsynaptic cell, 
initiating a new cellular response (1, 2). Neurons integrate vast quantities of information and can 
constantly change based on the amplitude of the signals and the frequency they are received (1, 
2). Neuronal signaling requires tight control and regulation with abnormalities resulting in a variety 
of neurological disorders. 
The brain is a plastic organ, meaning it changes in response to new information and 
responding to our ever-changing environment. The plastic changes occur at a network level by 
adding and pruning synapses to fine-tune the inputs a cell receives. Existing synapses can grow 
and become stronger when needed, and shrink when no longer required. Plasticity also occurs at 
the synapse level where neurons can fine-tune signaling in either the pre- or postsynaptic 
compartments (1, 2). On the presynaptic side, a synapse can be strengthened by adding to the 
number of vesicles containing neurotransmitters docked at the membrane increasing the release 
of neurotransmitters during synaptic transmission. On the postsynaptic side, adding or removing 
receptors to the membrane as well as modulating the receptors themselves (i.e. phosphorylation, 
G protein coupling) tunes the response in the postsynaptic neuron (1, 2). Together, the pre- and 
postsynaptic neurons fine-tune signaling to either potentiate or inhibit signaling. 
Tight control and regulation of neuronal signaling continues at the molecular level with the 
tight regulation of receptors. Synaptic transmission occurs by activating either ionotropic or 
metabotropic receptors. Ionotropic receptors are channels that open to allow the influx or efflux 
of ions upon neurotransmitter binding while metabotropic receptors induce changes in intracellular 
signaling. Both ionotropic and metabotropic receptors are activated rapidly after ligand binding 
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and quickly desensitize (1, 2). For example, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) ionotropic receptors open after glutamate binding but quickly desensitize thereafter. 
Desensitization is thought to aid in the unbinding of glutamate and the resetting of the receptor 
so that it can respond to a new signal (3-5). Metabotropic receptors follow the same principles of 
rapid activation and desensitization. Metabotropic receptors, also known as G protein coupled 
receptors (GPCRs), bind neurotransmitters resulting in the activation of a pre-coupled 
heterotrimeric G protein. The G protein then dissociates into G and G subunits, each of which 
initiates intracellular signaling through second messenger cascades (1, 2). -arrestin binds to the 
activated GPCR sterically hindering further G protein activation and effectively desensitizing the 
receptor (6, 7). Many GPCRs are internalized allowing the neurotransmitters to unbind from the 
receptor and resetting the GPCR for new signaling (8-10). Receptor recycling back to the 
membrane refreshes the receptor available at the membrane for neuronal signaling. Regardless 
of the neurotransmitter or the type of receptor, neuronal transmission requires tight control and 
regulation of receptors for appropriate signaling. 
1.2 G Protein coupled receptors and Dopamine D1 Receptor 
1.2.1 GPCRs, a textbook overview of signaling 
Before delving into GPCR signaling, a basic understanding of receptor signaling 
terminology is required. Receptors are typically cell surface sensors that allow cells to 
communicate and respond to environmental stimuli. A ligand is the stimuli that binds to the 
receptor to activate, inhibit, or otherwise modulate receptor signaling. Agonists are ligands that 
activate the receptor and induce an intracellular signaling cascade. Most endogenous ligands are 
agonists at their specific receptors. Antagonists, on the other hand, are ligands that bind a 
receptor and block or inhibit intracellular signaling at that receptor.  
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GPCRs are essential signaling proteins that are present in every cell type and tissue 
including the brain where they are fundamental to neurotransmission. GPCRs detect a vast array 
of stimuli ranging from light, odors, tastes, hormones, amino acids and peptides. Additionally, 
GPCRs are essential to numerous physiological processes in every tissue including 
neurotransmission in the brain and heart rate and contractibility in the heart among many others. 
Every neurotransmitter has a GPCR while only some have ionotropic receptors. Glutamate, -
aminobutyric acid (GABA), and acetylcholine are a couple examples of neurotransmitters that 
bind to both ionotropic and metabotropic receptors. Dopamine, endocannabinoids, and many 
peptide neurotransmitters act primarily through GPCRs (1, 2).  GPCRs are neuromodulators as 
they can alter excitability through G protein activated channels and can alter receptor 
phosphorylation and gene transcription. Normal physiology requires GPCRs such as the 
dopamine receptors for voluntary motor movement and diseases arise when GPCR signaling is 
not appropriate. 
There are over 800 validated GPCRs within the human genome (11). GPCRs are cell 
surface receptors that have seven transmembrane alpha helices with variable C terminal tails 
extending into the cytoplasm. GPCRs are cell surface receptors that bind an external stimuli (i.e. 
dopamine) and transduce that signal to the intracellular surface to mount an internal signaling 
cascade. To transduce this signal, GPCRs bind heterotrimeric G proteins on the intracellular 
surface that are comprised of G, G, and G subunits. The heterotrimeric G proteins often pre-
couple to GPCRs prior to ligand binding and pre-coupling increases affinity of many agonists for 
GPCRs (12).  Upon stimulation, the GPCR changes conformation activating the coupled G 
protein. The exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) in the 
G subunit activates the G protein. The G protein dissociates into G and G subunits that each 
induce downstream signaling cascades. Hydrolysis of GTP into GDP inactivates the G subunit 
and triggers re-association of the heterotrimeric G protein. Following G protein activation, -
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arrestin recruitment to the GPCR desensitizes further G protein signaling (1, 2, 13). This textbook 
overview of GPCR signaling leaves many details out to simplify and generalize GPCR signaling. 
1.2.2 Heterotrimeric G proteins and second messenger cascades 
GPCR signaling is considerably more complex than the simplistic overview above. For 
example, the heterotrimeric G protein is comprised of combinations of 21 G, 5 G, and 12 G 
subunits. Focusing in on the G subunits, the 21 isoforms can be broken down into four different 
classes, Gs, Gi, Gq, and G12 (Table 1) (14-16). Gs G proteins stimulate adenylyl cyclase to 
increase production of cyclic adenosine monophosphate (cAMP). Gs and Golf are members of 
this class. The Gi class is comprised of nine isoforms that inhibit adenylyl cyclase and thus cAMP 
production. The Gq family stimulates phospholipase C to produce inositol trisphosphate that 
releases calcium from the endoplasmic reticulum. Finally, the G12 family interacts with RhoA to 
induce actin cytoskeleton rearrangement (16). The G subunits are often overlooked when it 
comes to GPCR signaling but they are no less important and contribute to the complexity of GPCR 
signaling. As mentioned above, the heterotrimeric G protein dissociates into G and G subunits 
after GTP binds the G. The G subunits also induce downstream signaling including interacting 
with phospholipase C (16, 17). In addition, the G subunit can interact with G protein-gated 
inwardly rectifying potassium channels to hyperpolarize neurons and inhibit neuronal activity (17). 
Furthermore, the diversity of G and G subunits also indicate that they may play a role in fine-
tuning GPCR signaling. Heterotrimeric G protein signaling is extremely complex but most GPCRs 
have a preference for which class of G protein they typically pair with although, even this is being 
questioned now using knockout approaches in cells (18). For instance, the 2-adrenergic receptor 
and dopamine D1 receptor couple to Gs/olf G proteins to stimulate cAMP production while 




Table 1. G G protein subunits, members of each class, and basic function. 
 
1.2.3 -arrestin: from classical desensitization to controversial signaling 
The classical function of -arrestin is to desensitize GPCRs to further G protein signaling, 
attenuating second messenger cascades despite the continued presence of the agonist. In fact, 
arrestin was named for its ability to “arrest” GPCR activity. In 1986, the quenching, or 
desensitization, of rhodopsin-activated phosphodiesterase activity was reported when an 
“intrinsic 48 kDa protein” bound to the outer rod segments (19). The 48 kDa protein was later 
named arrestin and is one of two visual arrestin proteins. Shortly afterwards in 1990, the Lefkowitz 
lab discovered a homologous protein that desensitized the -adrenergic receptor, calling the 
protein -arrestin (6). In total, there are four arrestin proteins, two visual arrestin proteins 
expressed in the rods and cones of the retina and two non-visual arrestins (6, 20, 21). Arrestin1 
and arrestin4 are the visual arrestins while arrestin2 and arrestin3, also known as -arrestin1 and 
-arrestin2 respectively, are ubiquitously expressed throughout the body (20, 22, 23). Arrestins 
sterically hinder G protein binding explaining why arrestin binding blocks further G protein 
activation. G proteins bind to the intracellular loop 2, intracellular loop 3, and the C terminus while 
arrestin interactions are primarily through intracellular loop 2 (24-27). Crystal structures showing 
GPCRs bound to either G proteins or arrestins confirmed that they bind into the same pocket and 
G protein 
subunit 
Members of class Function 
Gs Gs, Golf ↑cAMP 
Gi 
Gi1, Gi2, Gi3, Go1, Go2, Gz, Gt1, Gt2, 
Gt3 
↓cAMP 
Gq Gq, G11, G14, G15 
↑ inositol trisphosphate and Ca 
release 
G12 G12, G13 




thus cannot both bind GPCRs at the same time (28, 29). Arrestins are cytoplasmic proteins that 
GPCRs rapidly recruit after agonist stimulation to desensitize G protein signaling. 
-arrestin recruitment to GPCRs occurs rapidly following receptor activation. Generally, -
arrestin does not bind to inactive receptors excluding some potential but low levels of constitutive 
activity. This indicates that something about receptor activation changes the affinity of -arrestin 
for the GPCR. Agonist activation changes the conformation of the receptor, which may allow -
arrestin recruitment. Agonist binding also induces phosphorylation of many GPCRs as well. 
Phosphorylation of rhodopsin increases the affinity of arrestin for rhodopsin while 
unphosphorylated rhodopsin does not efficiently bind arrestin (21, 30). This observation dates 
back even further to the original publication on arrestin in 1986. Wilden et al. observed that arrestin 
quenched G protein activation on phosphorylated rhodopsin but had no effect in 
unphosphorylated conditions (19). Furthermore, -arrestin recruitment to the 2-adrenergic 
receptor requires the receptor to be both active and phosphorylated (31). Interestingly, agonist-
induced phosphorylation of the dopamine D1 receptor (D1R) increased receptor desensitization 
and trafficking suggesting that phosphorylation is important for -arrestin recruitment to the D1R 
(32, 33). In contrast, truncating the C terminal tail of the D1R eliminated receptor phosphorylation 
but did not significantly alter desensitization or trafficking (24, 34). To reconcile these disparate 
finding, the authors suggested that removing the C terminal tail may open the previously hidden 
-arrestin binding site that C terminal phosphorylation would also open. Adding another layer of 
complexity, the phosphorylation of distinct residues control D1R desensitization and endocytosis 
(35). This study, however, did not investigate -arrestin recruitment, so it is unclear if both these 
phosphorylation sites recruit -arrestin despite the different outcomes or if other mechanisms are 
also involved. Phosphorylation appears to be important for GPCR arrestin recruitment resulting 
in classical desensitization, but arrestin recruitment is also important for receptor endocytosis. 
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The role of arrestin in GPCR signaling has further expanded to include receptor 
endocytosis. The general process begins with the recruitment of -arrestin to the activated and 
phosphorylated GPCR. -arrestin then recruits the receptor complex to clathrin-coated pits 
resulting in receptor endocytosis. The internalized receptor unbinds the agonist, is 
dephosphorylated, and recycled back the membrane to resensitize the cell. Alternatively, the 
receptor could be downregulated by degradation in the lysosome. The essential role of -arrestin 
in agonist-induced GPCR endocytosis is documented by multiple approaches. The Caron lab in 
1996 used a dominant negative -arrestin mutant to inhibit 2-adrenergic receptor endocytosis 
expanding the role of -arrestin beyond desensitization (36). Subsequent studies using siRNA in 
human embryonic kidney 293 (HEK293) cells and -arrestin1 and 2 knockout mouse embryonic 
fibroblast cells confirmed the role of -arrestins in GPCR agonist-induced endocytosis (37, 38). 
With the essential role of -arrestins in GPCR endocytosis established, researchers began 
looking at the mechanism of how -arrestin induces receptor endocytosis. 
-arrestins induce GPCR endocytosis by recruiting the receptor--arrestin complex to 
clathrin-coated pits. Indeed, -arrestin interacts with adaptor protein complex-2 (AP-2) and 
clathrin (39-41). AP-2 is an adaptor for clathrin-mediated endocytosis and these results indicate 
that GPCR bound -arrestins interacts both directly with clathrin and indirectly through AP-2. Kim 
and Benovic used site-directed mutagenesis of -arrestin1 and -arrestin2 to map the binding site 
of clathrin and AP-2 to the C terminus of -arrestins, but the sites did not overlap. The authors 
further determined that the clathrin binding site was essential for endocytosis while the AP-2 site 
had a less significant role in endocytosis (42). Further support for the role of the C terminus in 
endocytosis came from structural studies of -arrestin bound GPCRs. Upon binding the GPCR, 
the C terminus of -arrestin changes conformation making it more accessible for clathrin and AP-
2 binding (43, 44). After receptor endocytosis, the receptor needs to be sorted into either recycling 
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pathways for receptor resensitization or degradation pathways. For a review of resensitization 
and sorting see (45) and dephosphorylation see (46) but for the purpose of this dissertation, it is 
enough to say that these processes are tightly regulated and essential for GPCR signaling 
although out of the scope of this discussion. At this point, researchers linked -arrestins to both 
GPCR desensitization and endocytosis through clathrin-mediated endocytosis. 
 In addition to desensitization and receptor endocytosis, -arrestins also may induce their 
own G protein independent signaling cascades. In 1999, Luttrell et al. first reported the activation 
of extracellular signal-regulated kinase1/2 (ERK1/2) mitogenic signaling through src kinase 
activation and that src was recruited by -arrestin to the 2-adrenergic receptor (47). 
Furthermore,-arrestin2 coimmunoprecipitated with another mitogen-activated protein kinase 
(MAPK) pathway including c-Jun amino-terminal kinase 3 suggesting that -arrestin2 was acting 
as a scaffold for the activation of mitogenic signaling (48). An additional MAPK pathway, c-RAF1-
MEK1-ERK1/2 pathway used -arrestins as scaffold after stimulating the angiotensin II type 1a 
receptor (49). Together, these studies provided the foundation for the scaffolding role of -
arrestins in GPCR MAPK signaling. These studies changed the perception of -arrestins from 
shutting off GPCR signaling to also inducing their own signaling. Numerous studies followed the 
ones above supporting -arrestin dependent but G protein independent signaling (7, 50-53). 
However, recently the -arrestin dependent activation of ERK1/2 has become controversial. 
Studies using genome-editing techniques to knockout G proteins (Gs/olf, Gq, and G12/13) in 
combination with pertussis toxin, a Gi inhibitor, demonstrate no ERK1/2 activation (54-56). 
Furthermore, genetic deletion of -arrestin1 and 2 did not alter ERK1/2 phosphorylation compared 
to the parent cell line (56). The newer studies indicate that -arrestin modulates ERK1/2 activation 
but does not independently (from G proteins) activate ERK signaling. The disparity between the 
older studies that used pharmacological inhibitors and siRNA strategies and the newer genetic 
deletion strategies raises a controversial topic that is currently being argued in the literature. In 
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fact, Luttrell and colleagues from the Lefkowitz lab recently sent in a rebuttal paper defending -
arrestin signaling (57). Regardless of the outcome of this debate, -arrestins will remain essential 
regulators of GPCR signaling. 
1.2.4 GPCRs are drug targets 
GPCRs are important drug targets due their vital and varied roles in physiological 
processes throughout the entire body. The orthosteric binding pocket confers drug specificity 
when targeting GPCRs. The orthosteric binding pocket will only bind specific ligands and is 
relatively unique to each GPCR excluding some highly homologous GPCRs. The unique 
orthosteric binding pocket allows drugs to be targeted specifically to a GPCR and also activate or 
inhibit intracellular signaling. As cell surface receptors, GPCRs are easier to target than many 
intracellular proteins since a drug does not need to pass through the membrane to interact with 
GPCRs. Furthermore, GPCR signaling is amplified as it proceeds downstream. For instance, 
each GPCR activates multiple G proteins that activate adenylyl cyclase that greatly amplifies that 
signal by producing large quantities of the second messenger cAMP and so forth. Thus, the signal 
generated from one ligand results in a greatly amplified cellular response. In addition to signal 
amplification, GPCRs are involved in nearly every aspect of physiology in both health and 
disease. As such, both academic and industry groups are currently exploring GPCRs as drug 
targets. 
GPCRs are a large class of cell surface receptors with more than 800 validated members 
(11). As of 2017, GPCRs are the target of more than 30% of Federal Drug Administration (FDA) 
approved drugs with approximately 108 distinct GPCRs represented. An addition 321 agents were 
in clinical trials with 66 of those representing novel GPCR targets (58, 59). Furthermore, GPCR 
drugs comprise approximately 27% of the global drug market prior to 2017 earning $180 million 
annually (59, 60). Based on these numbers alone, one can conclude that GPCRs are important 
and validated drug targets. Drugs that target GPCRs include both agonists (activators) and 
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antagonists (inhibitors). A classic example for GPCR antagonists are typical antipsychotic 
medications that work, in part, by inhibiting dopamine D2 receptors (D2R) (61). The antipsychotic 
efficacy of the typical and atypical antipsychotics correlates with their ability to bind to the D2R 
(62). Aripiprazole is as effective as other atypical antipsychotics for managing positive symptoms 
but also improves negative symptoms. Interestingly, aripiprazole is a partial D2R agonist and is 
thought to exert its effect by blocking excessive D2R signaling (63). However, aripiprazole also 
binds to several other neurotransmitter GPCRs (63), a common phenomenon for antipsychotic 
medications. Regardless, antipsychotics all work, at least in part, by inhibiting excessive D2R 
signaling. Another example of medicines that target GCPRs are anticholinergics that target the 
muscarinic receptors. Many of the anticholinergics are non-selective between the muscarinic 
subtypes but they all work as antagonists to block the activity of acetylcholine. Anticholinergics 
treat a wide array of conditions including allergies, chronic obstructive pulmonary disease, motion 
sickness, Parkinson’s disease, and are used by ophthalmologist to dilate pupils during exams. 
Scopolamine is a non-selective muscarinic receptor antagonist used to treat post-operative 
nausea and is often applied as a patch placed behind the ear (64). There are numerous additional 
examples of drugs that target GPCRs. GPCRs comprise an important class of therapeutics that 
continues to grow with the development of new medications and novel GPCRs targets. As 
mentioned above, there are 108 distinct GPCRs targeted by FDA approved medications with 
approximately 66 additional novel GPCR targets currently in development. 
1.3 Biased GPCR signaling 
1.3.1 What is biased signaling? 
The basic paradigm of GPCR signaling begins with an agonist binding the receptor leading 
to the activation of the coupled G protein. The G protein then initiates a downstream signaling 
cascade. -arrestin binds the GPCR desensitizing the receptor to further G protein signaling and 
inducing receptor endocytosis. With this basic paradigm, a receptor is either “on or off” and 
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activates or inhibits both G protein and -arrestin pathways. To my knowledge, most endogenous 
agonists act in this fashion and activate both signaling pathways relatively equally. Agonists that 
equally activate G protein and -arrestin signaling are also known as balanced agonists. However, 
in the last ten to fifteen years, discovery of agonists that selectively activate one pathway over 
another have opened new and exciting therapeutic opportunities. Biased agonists are GPCR 
agonists that preferentially activate one pathway over another. For example, an agonist that 
selectively induces G protein signaling with reduced or absent engagement of the -arrestin 
pathway is a G protein biased agonist. Conversely, -arrestin biased agonists are agonists that 
selectively activate the -arrestin pathway. In the literature, selectively activating one pathway 
over another is called “functional selectivity” or “biased agonism” (65-67). Researchers in both 
academics and industry have immense interest in developing biased agonists. 
The molecular basis of biased agonism is not clearly defined and may be different for 
distinct receptors and agonists. However, biased agonism can be broken down into biased 
agonists, biased receptors, and biased systems (66). For example, an agonist may induce the 
receptor to signal in a biased fashion. In this case, different agonists may induce different 
conformations of the GPCR resulting in balanced agonism is some cases but biased agonism in 
others. The bias depends on the agonist. In addition, the receptor may be biased and any agonist 
that binds elicits a biased signaling response. The CXCR7 receptor signals primarily through -
arrestin without activation of G protein signaling (68). -arrestin may act as a scaffold for MAPK 
signaling, independent from G protein signaling (49). Finally, the system may produce bias by 
differentially expressing effectors and co-factors for GPCR signaling. An example of this is the 
differential expression of GPCR kinases in different tissues and cell types (69, 70). System bias 
means that an agonist could be biased in one cell type while balanced in another cell type 
depending on the expression of proteins such as GPCR kinases. While receptor and system bias 
are interesting and fundamental topics, this dissertation will focus exclusively on biased agonists 
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using both balanced and biased agonists at the human D1R. Furthermore, developing biased 
agonists hold more promise as a therapeutic strategy over trying to change receptor or system 
bias due to the relative ease of manipulating agonists over changing receptors themselves or the 
system.  
1.3.2 Biased agonists offer new therapeutic opportunity 
Biased agonism offers control over receptor signaling at a level previously unattainable. 
Selectively activating or inhibiting G protein or -arrestin signaling allows researchers the ability 
to fine-tune drug action and the resulting physiological effects. However, researchers first need 
to understand what contributions to signaling and physiology each pathway has before advancing 
biased therapeutics. Behavior and physiology are the culminating result of many cellular 
processes and G protein signaling may contribute to one behavior while -arrestin signaling 
contributes to another. However, it is also possible that both G protein and -arrestin signaling 
are required for some processes. For instance, Rose and colleagues from the Caron lab recently 
developed a technique to investigate G protein versus -arrestin signaling of the D2R in vivo. 
Most behaviors they studied depended on both G protein and -arrestin signaling including 
locomotion and rearing while nestlet shredding only depended on G protein signaling (71). 
Perhaps a better example for the therapeutic potential for biased signaling is the -opioid receptor. 
G protein biased agonists at the -opioid receptor provide analgesia with reduced respiratory 
suppression and constipation (72-75). Together, these results indicate that G protein signaling is 
important for analgesia while -arrestin signaling is important for adverse effects at the -opioid 
receptor. The development of biased agonists is accelerating research on G protein and -arrestin 
signaling contributions to behavior as researchers now have the tools available to interrogate 
these questions in vivo. Biased agonists have the potential to fine-tune GPCR signaling creating 
medicines with increased efficacy or reduced side effect profiles.  
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1.4 The function of dopamine D1 receptors 
1.4.1 Dopamine receptors 
Dopamine is an essential neurotransmitter that works through five distinct GPCRs. The 
dopamine D1 and D5 receptors both couple to the Gs family of G proteins to stimulate adenylyl 
cyclase and increase cAMP production. The D1 and D5 receptors are practically 
pharmacologically indistinguishable leading many people to group them into the D1-like receptors 
family (76). Dopamine D2, D3, and D4 receptors are the D2-like receptor family. D2-like receptors 
couple to the Gi family of G proteins to inhibit adenylyl cyclase and decrease cAMP production. 
Thus, dopamine can either stimulate or inhibit cAMP production depending on if it binds D1-like 
or D2-like receptors. Medium spiny neurons in the direct pathway express the D1R while the D2R 
is expressed in the medium spiny neurons of the indirect pathway(76). Together, the D1R and 
D2R are integral for proper motor control and movement among other fundamental processes. 
As mentioned, the D1R is a Gs/olf coupled GPCR. D1R stimulation increases the 
production of cAMP leading to activation of protein kinase A and cAMP response binding protein 
(CREB), among other signaling process (77). CREB is a transcription factor that alters gene 
transcription when it is activated by phosphorylation at serine 133 (78). In addition, the D1R 
recruits -arrestin to desensitize the receptor and may be involved in regulating D1R endocytosis 
(24, 76). 
1.4.2 Dopamine in the body 
The D1R is expressed in multiple locations in the body including in the brain, retina, 
cardiovascular system and the kidneys (24). The D1R is abundantly expressed in the brain, 
especially in the striatum and prefrontal cortex (described below). Furthermore, the kidneys 
express all dopamine receptor subtypes including the D1R. In the kidneys, the D1R inhibits 
sodium transport to facilitate sodium excretion. Through this role, the D1R participates in 
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regulating blood pressure and is implicated in hypertension. In fact, the only current FDA 
approved D1R-selective agonist is fenoldopam that acts on the peripheral D1R to reduce 
hypertension in acute inpatient hospital settings (79). While it is easy for neuroscientists to forget 
about peripheral receptors, a potential pitfall for D1R agonists is hypotension when targeting 
central nervous system D1Rs. Thus, it is essential to test centrally active D1R agonists for their 
effects on blood pressure as well as the brain. 
1.4.3 The role of dopamine and the D1R in the brain 
The brain takes in and processes a plethora of information to create our perception of the 
world and control how we interact with it. Dopamine is a critical neurotransmitter with roles in 
voluntary motor control, cognition, working memory, attention, motivation, and reward processing 
among others (76, 80-90). There are four major dopaminergic tracts in the brain, nigrostriatal, 
mesocortical, mesolimbic, and tuberoinfundibular pathways. The nigrostriatal pathway stretches 
from the substantia nigra to the striatum where it modulates voluntary motor pathways. The 
substantia nigra contains dopamine-producing cells that degenerate during Parkinson’s disease 
leading to difficulties in initiating voluntary motor movements. The mesocortical pathway extends 
from the ventral tegmental area to the prefrontal cortex where is plays a role in modulating 
cognition. Prefrontal cortical D1Rs are essential for working memory and attention (82, 87-89, 91-
93). D1R antagonists induce working memory deficits in healthy young adults (94). In addition, 
patients with schizophrenia had increased D1R in the prefrontal cortex compared to age-matched 
control subjects. The authors suggest that the increased D1R is a failed compensatory 
mechanism designed to increase D1R signaling in the prefrontal cortex of patients with 
schizophrenia (95). Furthermore, D1R agonists rescued working memory deficits in patients with 
schizophrenia (85). Together, these studies suggest that dopamine is essential to working 
memory and indicate that targeting dopamine neurotransmission is a promising therapeutic target 
for the treatment of cognitive deficits in schizophrenia. The third major dopaminergic pathway is 
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the mesolimbic pathway that extends from the ventral tegmental area to the amygdala and 
nucleus accumbens. The mesolimbic pathway is important for reward and motivation. Numerous 
substances of abuse alter the mesolimbic pathway including nicotine, cocaine, and morphine 
among others (96-98). Modulating dopamine signaling in the mesolimbic pathway may be a 
therapeutic strategy for treating substance use disorders. Although, each type of substance 
affects the pathway differently and may require substance-specific therapies. The fourth major 
dopaminergic pathway is the tuberoinfundibular pathway that extends from the arcuate nucleus 
of the hypothalamus to the infundibular region (median eminence). The tuberoinfundibular 
pathway primarily expresses D2R that control prolactin release from the pituitary gland (99). 
Dopamine is undoubtedly an essential neurotransmitter in the brain in control of a multitude of 
functions. When dopamine signaling goes awry, distinct clinical disorders appear depending on 
the location of the altered signaling underscoring the importance of appropriate dopaminergic 
signaling in the brain. 
1.5 Neuropharmacology of the D1R 
1.5.1 Dopamine is a catecholamine 
Dopamine, along with norepinephrine and epinephrine, are catecholamines named for the 
shared catechol structure. A catechol is a dihydroxyphenyl chemical moiety. Dopamine synthesis 
consists of a series of enzymatic reactions that starts with the conversion of tyrosine into 
dihydroxyphenylalanine (DOPA) and ultimately ending in dopamine. Phenylalanine can be used 
instead of tyrosine if there is a shortage of tyrosine (100). Tyrosine hydroxylase is a commonly 
used marker for dopamine producing neurons and is the enzyme responsible for converting 
tyrosine to DOPA. Interestingly, a standard of care for Parkinson’s disease is treatment with L-




1.5.2 D1R drug development efforts 
1.5.2.1 Benzazepines 
For more than 40 years, academic and industry scientists have been attempting to develop 
drugs targeting the D1R. The first selective D1R agonist discovered was SKF-38393. 
Interestingly, SKF-38393 was first discovered for its ability to increase renal perfusion and later 
tested in the brain on a 6-hydroxydopamine (6-OHDA) lesion model of Parkinson’s disease (101, 
102). SKF-38393 is a partial agonist compared to dopamine. SKF-38393 gave rise to the 
benzazepines, a class of ligands based on a shared chemical structure and are widely used in 
experimental settings. In addition, all benzazepine agonists include a catechol moiety like 
dopamine. Dozens of benzazepine derivatives were developed; however, poor oral bioavailability 
and a propensity to cause seizures limited the therapeutic development of these agonists (103). 
SKF-81297 is a full D1R agonist in the benzazepine class but was not developed until 
approximately ten years later. The benzazepine pharmacophore also includes D1R antagonists 
such as SCH-23390 and ecopipam (104, 105). The benzazepine agonists are still widely used in 
lab settings today to study D1R signaling. 
1.5.2.2 Dihydrexidine 
The next advancement in D1R agonist development was dihydrexidine. Dihydrexidine was 
the first full D1R selective agonist that was also brain penetrant (106, 107). Although dihydrexidine 
is also a catechol agonist with poor pharmacokinetics, the ability to cross the blood-brain barrier 
made it a valuable agonist for investigating the potential of D1R-targeted therapies. Dihydrexidine 
was the first D1R agonist to improve motor deficits associated with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) lesioning, a model of Parkinson’s disease, in non-human primates 
(108). At the time, the D2R was thought to mediate the antiparkinsonian effects of dopamine 
agonists, but dihydrexidine provided evidence that the D1R played a critical role. Due this 
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antiparkinsonian activity, dihydrexidine advanced into Phase I and Phase II clinical trials for 
Parkinson’s disease. Dihydrexidine was ultimately pulled out of clinical development due to poor 
pharmacokinetics, dose limiting hypotension, and tachycardia (109). A pro-drug was developed 
with a similar structure to dihydrexidine called, ABT-431. Similar to dihydrexidine, ABT-431 had 
antiparkinsonian properties but still lacked oral bioavailability (110). Aside from the 
antiparkinsonian effects, dihydrexidine also possesses cognitive enhancing effects, primarily on 
working memory. In young and aged non-human primates, dihydrexidine improved cognition. The 
authors further determined that the cognitive improvements observed in dihydrexidine treated 
non-human primates was mediated specifically by the D1R, since the D1R selective antagonist 
SCH-23390 blocked the effect of dihydrexidine (111). Further, in a proof-of-concept study, 
dihydrexidine improved working memory deficits in patients with schizophrenia (112). These 
results indicate that D1R agonists can improve working memory deficits associated with 
neuropsychiatric disorders. Again, the catechol moiety of dihydrexidine prevented clinical 
development due to poor pharmacokinetics, but dihydrexidine advanced D1R research as the first 
brain penetrant D1R selective and full agonist. 
1.5.2.3 Benzazepine derivatives: A-68930 and A-77636 
After the development of dihydrexidine, A-68930 and A-77636 were developed and 
overcame the oral bioavailability issues observed with other catechols. A-68930 and A-77636 are 
selective D1R agonists with full efficacy compared to dopamine. Both A-68930 and A-77636 
possess antiparkinsonian properties in animal models. A-68930 and A-77636 induced rotational 
behavior in 6-OHDA lesioned rats and improved motor deficits in MPTP lesioned non-human 
primates (113-115). Additionally, A-77636 improves spatial working memory in non-human 
primates at low to moderate doses (116). A-77636 is orally bioavailable overcoming the previous 
limitation of catechol agonists (113). However, several early studies also observed that A-77636 
produced profound and rapid tolerance even by the second dose (113, 117, 118). A-77636 binds 
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the D1R near irreversibly, which may explain, in part, the rapid D1R desensitization and in vivo 
tachyphylaxis. A-68930, but not A-77636, induced seizures precluding it from further in vivo 
testing (114). However, A-77636 is still widely used in experimental settings including in vitro and 
animal models (86, 105). Despite overcoming bioavailability issues associated with other catechol 
agonists, A-77636 induced rapid tolerance preventing its advancement into the clinic. 
1.5.2.4 Catechols have problems: metabolism and pharmacokinetics issues 
Despite more than 40 years of effort by academic and industry groups, there are still no 
FDA-approved brain penetrant and centrally active D1R selective agonists. The common 
chemical structure shared by all previous D1R selective agonists is the catechol moiety. The 
catechol agonists, as a class, are associated with poor oral bioavailability, rapid metabolism in 
the serum, and tolerance. While these setbacks prevented the advancement of a catechol agonist 
into the clinic for neurological disorders, the catechols greatly advanced our understanding of the 
role D1Rs have in health and disease. Catechol agonists were vital in establishing the critical role 
of the D1R in voluntary movement and cognition including working memory and attention. 
However, new drug-like agonists that can overcome the pitfalls of the catechol agonists are 
needed before D1R agonists can enter the clinic. 
Recently, the discovery of non-catechol D1R selective agonists provided a breakthrough 
for the treatment of Parkinson’s disease and neuropsychiatric disorders. The first non-catechol 
agonist lead was originally discovered at Pfizer in a large high throughput screening campaign 
(86). Subsequently, Pfizer generated numerous analogs of the lead to optimize both full and 
partial non-catechol agonists and recently described the analogs in publications and patents (86, 
119-122). The non-catechol D1R agonists overcome the problems associated with catechol 
agonists and have good oral bioavailability, serum half-life, and interestingly, decreased tolerance 
(86). However, it remains to be seen if a non-catechol D1R agonist will become an approved 
medication, but some have advanced through Phase I and Phase II clinical studies at Pfizer and 
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more recently at Cerevel, a spinoff biotechnology company (123-126). Interestingly, the 
underlying signaling mechanisms of the non-catechol agonists are still not fully understood and 
will be discussed in great detail below. 
1.5.2.5 D1R positive allosteric modulators 
In addition to the recently discovered non-catechol agonists, D1R positive allosteric 
modulators, are also currently in development. Positive allosteric modulators (PAM) are ligands 
that bind outside of the orthosteric binding pocket and increase the efficacy and/or affinity of 
agonists that bind the receptor. A PAM allosterically modifies a receptor to increase the binding 
affinity or efficacy of the endogenous ligand. PAMs keep the spatial and temporal resolution of 
neurotransmission and increase receptor sensitivity to the ligand (leftward shift potency) and/or 
increase the maximum signaling efficacy through second messengers (127-129). Several 
companies are pursuing D1R PAMs as a potential therapeutic strategy to enhance endogenous 
dopamine signaling. Eli Lilly has several Phase I and Phase II clinical trials evaluating LY3154207. 
The Phase II trial is targeting cognitive deficits in Parkinson’s disease dementia. Furthermore, 
Astellas has another D1R PAM currently in Phase II clinical trials for cognitive impairment in 
schizophrenia (105, 130). Several other D1R PAMs are also being actively investigated. D1R 
PAMs are another active avenue for the discovery of clinically relevant therapies for Parkinson’s 
disease and schizophrenia among others. Maintaining the spatial and temporal signaling of the 
endogenous ligand dopamine may prove therapeutically beneficial. However, PAMs may not be 
as effective in the late stages of neurodegenerative diseases such as Parkinson’s disease when 
the cells that produce dopamine have degenerated. D1R PAMs are not catechols and many 
possess good pharmacokinetics, overcoming a pitfall that has hampered the development of D1R 
targeted therapeutics. Together with the non-catechol D1R agonists, D1R PAMs are an exciting 




1.6 Hypothesis and aims 
For more than 40 years, researchers have searched for drug-like agonists for the D1R. 
The catechol moiety common to all previous agonists prevented the development of D1R agonists 
with good pharmacokinetics. The recent discovery of non-catechol D1R agonists is a 
breakthrough that has created drug-like molecules with good pharmacokinetics and decreased 
tolerance (86). Here, we extend these findings by characterizing several non-catechol agonist 
analogs and use these ligands to determine the effects of D1R G protein biased signaling on 
receptor endocytosis. We further validate the dependence of D1R endocytosis on -arrestin using 
advanced CRISPR/Cas9 knockout studies. The hypothesis and aims are outlined below. 
Aim 1: The first aim tests the hypothesis that -arrestin1/2 are required for agonist-
induced D1R endocytosis. The initial experiments aim to verify the knockout of -arrestin1 and -
arrestin2 from HEK293 cells using CRISPR/Cas9 genome editing. cAMP kinetic assays in the 
knockout cells examine the effect of -arrestin1/2 knockout over a 60-minute treatment on cAMP 
levels. Further, desensitization assays in parent HEK293 and -arrestin1/2 knockout cells confirm 
a role for -arrestin1/2 in D1R desensitization. Next, confocal imaging analysis on parent HEK293 
and -arresin1/2 knockout cells investigates agonist-induced endocytosis. Finally, a cell surface 
ELISA assay quantifies agonist-induced endocytosis by measuring D1R receptors remaining at 
the membrane after agonist treatment. Together, these studies aim to determine if -arrestin is 
essential for D1R signaling and endocytosis. 
 Aim 2: Aim 2 tests the hypothesis that D1R G protein biased agonists will induce less 
receptor endocytosis than balanced agonists. The first studies characterize G protein and -
arrestin signaling by several catechol and non-catechol D1R agonists. HEK293 cells are treated 
with agonists to investigate the effect of balanced or G protein biased D1R agonists on receptor 
endocytosis using confocal imaging. Finally, catechol and non-catechol agonists effects on 
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receptor endocytosis is quantified using the cell surface ELISA assay. The goal of these studies 
is to profile the balanced and G protein biased D1R agonists and to determine the effect of biased 
signaling on D1R endocytosis. 
1.7 Goals of this study 
The overall goals of this study are to investigate G protein biased signaling by non-
catechol D1R agonists. This can be broken down into three separate goals detailed below. 
1) Determine if -arrestin1/2 are required for D1R agonist-induced endocytosis and 
determine the role of -arrestin1/2 in regulating cAMP production (i.e. desensitization). 
2) Characterize G protein and -arrestin signaling for several catechol and non-catechol 
D1R agonists. 
3) Determine the effect of G protein biased agonism on D1R endocytosis. 
These studies build on the concepts of GPCR biased signaling and extend our knowledge of D1R 
G protein biased agonists. These results provide a foundation for the comparison of well-
established catechol agonists and the more recent non-catechol agonists and open the door to 
further mechanistic studies investigating the molecular mechanisms of G protein biased signaling. 
Furthermore, these studies characterize several potent and efficacious balanced and G protein 
biased non-catechol agonists, providing opportunities in the future to explore the in vivo effects of 









2.1 Materials and Cell Culture 
The commercially available agonists/chemicals were purchased from the following suppliers: 
SKF-81297 (Sigma), SKF-38393 (Tocris), SKF-77434 (Tocris), ascorbic acid (Sigma). D1R non-
catechol agonists, which are not commercially available, were synthesized at the University of 
Texas Medical Branch by Dr. Jia Zhou’s laboratory.  PF-1119, PF-2334, PF-6142 were 
synthesized by according to protocols described in Gray, Allen et al (86). 6-(4-(Furo[3,2-
c]pyridin-4-yloxy)-2-methylphenyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione (Cmpd 19) and 6-
(4-((3-(Difluoromethoxy)pyridin-2-yl)oxy)-2-methylphenyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-
dione (Cmpd 24) were synthesized as described previously by Wang, Felsing et al. (131) and in 
previous patents by Pfizer, Inc (120-122). 6-(4-(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-
methylpyrazin-2-amine (Cmpd 1), 4-(4-(Imidazo[1,2-a]pyridin-5-yl)-3-(trifluoromethyl)phenoxy)-
furo[3,2-c]pyridine (Cmpd 2), and 7-(4-(Imidazo[1,2-a]pyridin-5-yl)-3-(trifluoromethyl)phenoxy)-
thieno[2,3-c]pyridine (Cmpd 3) were synthesized according to synthetic protocols described by 
Martini et al (132).c  All synthesized compounds were verified for purity (>95%) and chemical 
structures verified using NMR and MS analytical techniques (86, 131). 
Parent HEK293 cells and -Arr1/2 KO cells were a generous gift from Asuka Inoue 
(Tohoku University) (55) and were maintained in DMEM supplemented with 10% fetal bovine 
serum (Omega) and 1% penicillin/streptomycin (Gibco). The -Arr1/2 KO cells were generated by 
using CRISPR/Cas9 genomic editing to delete ARRB1 and ARRB2 (the genes encoding -Arr1 
and -Arr2) sequentially from the Parent HEK293 cell line. Stable D1 HEK293 (D1-HEK) cells 
were maintained in DMEM supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin, 1% MEM NEAA (Gibco), 25 mM HEPES (Gibco), and 500 ug/ml Geneticin 
(Gibco). HTLA cells (HEK293 cells stably expressing tTA-dependent luciferase reporter and a β-
arrestin2-TEV fusion gene) were maintained in DMEM supplemented with 10% fetal bovine 
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serum, 1% penicillin/streptomycin, 2 ug/ml Puromycin (Gibco), and 100 ug/ml Hygromycin 
(Thermofisher). 
2.2 SDS-PAGE and western blotting 
Parent HEK293 and -Arr1/2 KO cells were harvested and pelleted in cold PBS. Cell 
pellets were lysed in 1X RIPA buffer, pH 7.5 (25 mM Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 
1% NP-40 alternative, 1% sodium deoxycholate, 0.1% SDS and 10% glycerol). Protease inhibitor 
cocktail and 1 mM PMSF were added to RIPA buffer just prior to cell lysis. Cell pellets were 
incubated on ice for 15 minutes in the RIPA buffer, followed by sonication with a microtip for 15 
seconds on ice. The cell lysates were centrifuged at 12000g for 10 minutes, the supernatants 
were collected and protein concentration determined by bicinchoninic acid assay. Ten percent 
SDS-PAGE was performed and then transferred to PVDF membranes. Membranes were blocked 
in 5% milk in 1X tris buffered saline Tween-20 buffer (TBST) (25 mM Tris, 0.15 M NaCl, 0.05% 
Tween-20, pH 7.5) at room temperature for 1 hour. Membranes were incubated overnight at 4˚C 
with the indicated primary antibody. Primary antibodies were β-Arr1 (1:1000), β-Arr2 (1:1000) and 
β-actin (1:1000). The membranes were washed 3 times in TBST and then incubated with 
secondary antibody for 1 hour at room temperature. Anti-rabbit IgG conjugated to horseradish 
peroxidase-conjugated (HRP) (1:1000) was used to detect β-Arr1 and β-Arr2. HRP signal was 
detected by chemiluminescence (SuperSignal West Pico Substrate). Membranes were reprobed 
with β-actin, followed by goat anti-rabbit IgG IR800 (Abcam, 1:2000) incubation. Membranes were 
scanned using LI-COR Odyssey FC Imager (Cambridge, UK). 
2.3 D1R endocytosis confocal imaging 
To investigate the -arrestin dependence of agonist-induced endocytosis, we conducted 
antibody feeding which is an imaging based endocytosis assay. Parent HEK293 cells and -Arr1/2 
KO cells were plated into 6-well plates at 400,000 cells per well. After 24 hours, the cells were 
24 
 
transfected with 0.25 µg HA-D1R plasmid per well in a 6-well plates using 7.5 ul 
Lipofectamine2000 as per manufacturer’s protocol and returned to the incubator overnight. The 
following morning cells were plated on poly-L-lysine coated coverslips in 24-well plates at 50,000 
cells per well and returned to the incubator for 24 hours. The cells were then serum starved for 1 
hour in DMEM without serum or antibiotics. After aspirating the media, ice-cold 1X HBSS with 20 
mM HEPES was added gently to the cells and incubated on ice for 15 minutes. Anti-HA 
conjugated to Alexa488 (1:200, Cell Signaling) diluted in HEPES/HBSS was then added to the 
cells for 45 minutes in the dark on ice. After 3 washes in ice-cold HEPES/HBSS for 5 minutes 
each, 10 µM SKF-81297 or A-77636 was added to the cells which were returned to 37°C for 60 
minutes in the incubator. The cells were fixed immediately in 4% paraformaldehyde for 20 
minutes, followed by 3 washes in PBS for 5 minutes. The coverslips were mounted on slides using 
Vectorshield mounting medium with DAPI (Vector laboratories Inc.). Cells were imaged with a 
63X oil objective on a Leica True Confocal Scanner SPE and Leica Application Suite Advanced 
software (Leica Microsystems, Germany). Z-stacks were obtained with 0.2m steps with a zoom 
factor of 1.5. Representative images were adjusted for brightness and contrast for publication. 
To further validate that the deficit in agonist-induced D1R endocytosis in the -Arr1/2 KO 
cells is dependent on -arrestin and control for potential off-target effect of CRISPR/Cas9 
mediated KO of -Arr1/2, we expressed -arrestin1 and/or -arrestin2 in the -Arr1/2 KO cells. 
Parent HEK293 and -Arr1/2 KO cells were transfected with 0.5 µg empty vector in addition to 
0.25 g HA-D1R as indicated. -Arr1/2 KO cells were transfected with 0.5 µg -Arr1, 0.5 µg -
Arr2, or 0.5 µg of both -Arr1 and -Arr2 as indicated in addition to 0.25 g HA-D1R. Antibody 
feeding was conducted identically to the above. 
For agonist-induced endocytosis experiments, parent HEK293 cells were transfected with 
0.25 g HA-D1R plasmid. Antibody feeding was then conducted using 10 M of the indicated 
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agonists (dopamine, SKF-81297, A-77636, PF-1119, PF-2334, PF-6142, Cmpd 19, and Cmpd 
24). 
2.4 Cell surface enzyme-linked immunosorbent assay (ELISA) 
We used the cell surface ELISA to quantify D1R endocytosis in the parent HEK293 and 
-Arr1/2 KO cells. Parent HEK293 and -Arr1/2 KO cells were plated in 6-well plates at 550,000 
cells per well and incubated for 24 hours at 37°C. Parent HEK293 and -Arr1/2 KO cells were 
transfected with 0.25 µg HA-D1R plasmid and 7.5 l Lipofectamine2000 as per manufacturer’s 
protocol per well of a 6-well plate and incubated overnight. The cells were then split into 96-well 
plates coated with poly-L-lysine at 65,000 cells per well and incubated for 24 hours. The cells 
were serum starved for 1 hour in DMEM then treated with 10 µM A-77636 for the indicated times 
(0-60 minutes) and fixed with 4% paraformaldehyde in PBS for 20 minutes at room temperature. 
Cells were washed 3 times with PBS for 5 minutes each, followed by blocking for 1 hour in 5% 
bovine serum albumin diluted in PBS at room temperature. The plates were incubated overnight 
at 4°C with rabbit anti-HA antibody (1:1000, Cell Signaling) diluted in blocking buffer. In the 
morning the cells were washed 3 times with PBS for 5 minutes each. Anti-rabbit HRP (1:1000; 
Cell Signaling) diluted in PBS containing 0.01% Hoechst fluorescence nuclear stain was added 
to the cells for 1 hour at room temperature. After 3 washes with PBS for 5 minutes each, Hoechst 
staining was read with an excitation 392 nm and emission 440 nm on a Synergy H4 plate reader 
(Biotek, Winooski, VT). The cells were then incubated in 3’3,5’5-tetramethylbenzidine liquid 
substrate (Sigma-Aldrich) in the dark at room temperature for 30 minutes and then absorbance 
was measured at 370 nm on the Synergy H4 plate reader. The background absorbance was 
determined by measuring non-transfected cells and was subtracted from each well. Each well 
was then normalized to the Hoechst signal to account for cell number variation. Following this, 
the results were expressed as % loss of cell surface HA-D1R with the 0 minute time point 
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considered 0% loss of the receptor at the membrane. The results were analyzed using GraphPad 
Prism 7 using a two-way ANOVA with Tukey’s posttest. 
To further validate the role of -arrestin in agonist endocytosis, we expressed -arrestin1 
or -arrestin2 in the -Arr1/2 KO cells. Parent HEK293 and -Arr1/2 KO cells were transfected 
with 0.5 µg empty vector in addition to 0.25 g HA-D1R as indicated. -Arr1/2 KO cells were 
transfected with 0.5 µg -Arr1 or 0.5 µg -Arr2 as indicated in addition to 0.25 g HA-D1R. The 
cell surface ELISA was conducted identically to the above. 
For agonist-induced endocytosis experiments, parent HEK293 cells were transfected with 
0.25 g HA-D1R plasmid. The cell surface ELISA was then conducted using 10 M of the 
indicated agonists (dopamine, SKF-81297, A-77636, PF-1119, PF-2334, PF-6142, Cmpd 19, and 
Cmpd 24) added at the indicated times (0-120 minutes). 
2.5 D1R cAMP agonist dose-response assay 
 D1-HEK cells were split into poly-L-lysine coated 6-well plates at 450,000 cells per well. 
After 24 hours incubation, the D1-HEK cells were transfected using 1.0 ug Glosensor plasmid and 
10 ul Lipofectamine2000 (Thermofisher) as per manufacturer’s protocol. The D1-HEK cells were 
transfected overnight and split the following morning into poly-L-lysine (Culturex) coated 96-well 
plates at 50,000 cells per well. Approximately 48 hours after transfection, the media was 
discarded and Glosensor reagent (Promega) diluted to 1% in 20 mM HEPES in 1X HBSS (Gibco) 
was added for 2 hours at room temperature. Agonist treatment consisted of eleven point dose-
response curves that were incubated 10 minutes at room temperature. Agonist response 
(bioluminescence) was measured on the Microbeta2 plate reader (Perkin Elmer). The data were 
transferred to Graphpad Prism8 where the dose-response curves were analyzed using “dose-
response – stimulation” nonlinear regression analysis with three parameters. The data were then 
normalized using SKF-81297 as 100% and the mean basal counts as 0%. Nonlinear regression 
was performed on the normalized data to express all agonists as a % of SKF-81297. Cmpd 1 and 
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3 were not soluble at high concentrations in 0.1% DMSO unlike all other tested agonists. 
Increasing the DMSO concentration to 0.5% increased solubility enough to conduce full dose-
response curves. All other agonists were in 0.1% DMSO vehicle. 
2.6 -arrestin recruitment Presto-Tango assay 
 The procedure was adapted from Kroeze et al. (133). Briefly, 375,000 cells per well were 
split into 6-wells plates and incubated for 24 hours. The HTLA cells were then transfected using 
calcium phosphate transfections methods. Briefly, 1.4 ug of D1R-TANGO plasmid and 120 uM 
CaCl2 (diluted with H2O from 2 mM stock) were mixed in one centrifuge tube. In a separate tube, 
2X HEPES buffered saline (HBS, 280 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4, 50 mM HEPES) 
was added in equal volume to the tube containing the DNA. The contents of the tubes were then 
mixed together and vortexed. The mixture was added immediately, dropwise, to the HTLA cells 
which were returned to the incubator overnight. The transfected HTLA cells were split into a poly-
L-lysine coated 96-well plate at 80,000 cells per well and returned to the incubator. Forty-eight 
hours post transfection, the HTLA cells were treated with the indicated agonist using an 11 point 
dose-response curve. Due to the long treatment time, 100 M ascorbic acid (Sigma, final 
concentration) was added to the 1X HBSS used to dilute the agonists. After 18-20 hours post-
treatment, the cells were lysed using the Bright-Glo luciferase substrate (Promega) diluted 20-
fold in 1X HBSS for 20 minutes at room temperature and read using the Microbeta2 plate reader 
to detect bioluminescence. The results were transferred to GraphPad Prism8 and analyzed 
identically to the Glosensor cAMP assay. 
2.7 D1R cAMP desensitization 
To assess D1R desensitization in the presence of A-77636, cells were transfected with 
0.25 µg HA-D1R plasmid along with 1.0 µg of pGlosensor™-22F plasmid. Cells were cultured in 
DMEM containing 10% dialyzed FBS and 1% penicillin/streptomycin. After 12 hours of 
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transfection, 50,000 cells per well were seeded onto poly-L-lysine coated white-wall, clear bottom 
96 well plates (Greiner Bio-One, Monroe, NC) overnight. Forty-eight hours post-transfection, the 
media was aspirated out and cells were serum starved with 90 l of 1% Glosensor reagent in 1X 
HBSS + 20 mM HEPES buffer for 1 hour. To initiate desensitization, cell were treated with 10 M 
A-77636 or vehicle at indicated time points (5 minutes – 240 minutes). Upon completion of 
desensitization time-course, media was discarded and cells were washed 4 consecutive times 
with 100 l PBS for 5 minutes in an incubator. Cells were then loaded with 90 l of 1% Glosensor 
reagent in 1X HBSS + 20mM HEPES buffer and re-challenged with 10 M A-77636 for 10 
minutes. As a negative control, a subset of cells was incubated with only vehicle, and rechallenged 
with either forskolin, A-77636, or vehicle. Luminescence was read on a Microbeta2 Microplate 
Counter (PerkinElmer Life Sciences). Percent desensitization was calculated using the vehicle 
pre-treated cells with the A-77636 challenge as 0% desensitization. A two-way ANOVA with 
Bonferroni’s multiple comparisons test was used to analyze the results from three independent 
experiments preformed in triplicate. 
2.8 Spearman’s correlation 
 Spearman’s correlation was conducted on the -arrestin recruitment Emax (x) and % loss 
of cell surface HA after 120 minute treatments (y). Spearman’s correlation analysis was 
completed in GraphPad Prism8. A linear regression line based on the correlation analysis was 







3. RESULTS - -arrestin is essential for D1R agonist-induced endocytosis. 
3.1 Introduction 
GPCRs are widely expressed throughout the body including the brain (134). The D1R is 
an essential catecholamine GPCR in the brain responsible for many vital functions including 
voluntary movement, working memory, attention, and reward processing among others (76, 80, 
88). GPCR signaling involves two fundamental pathways including G proteins and -arrestins. -
arrestins are ~48kDa proteins found in the cytosol. Following activation of the GPCR and G 
protein, -arrestins are recruited to the membrane where they bind to GPCRs preventing further 
G protein activation. Arresting G protein signaling is the canonical function of the arrestin protein 
family and the original function described resulting in the name, arrestin (6, 19). -arrestin binds 
to GPCRs in the same pocket as the G protein to sterically hinder further G protein binding and 
activation (6, 7, 21, 135). In addition, -arrestin can act as an adaptor for clathrin-mediated 
endocytosis of the receptor (8-10). After endocytosis, the receptor can be recycled back to the 
membrane, resensitized for a new round of signaling or degraded in the lysosome leading to 
receptor downregulation(9). 
Advances in genomic editing and knockout (KO) strategies have allowed researchers to 
revisit the fundamental roles of -arrestin1/2 (-Arr1/2) and other transducers for a wide variety 
of receptors (55-57). Historically, researchers used small interfering RNA (siRNA) strategies to 
elucidate the function of proteins. Unfortunately, siRNA strategies maximally knockdown gene 
expression by 80% leaving at least 20% of the protein to potentially confound observed results 
(50). With the advancement of genome editing techniques, it is now possible to KO the expression 
of a specific gene to understand its function in vitro and in vivo (55-57, 136, 137). Clustered 
regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) genome editing is a 
powerful tool to study the fundamental roles of -Arr1/2 without the confounding factor of residual 
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protein expression as with siRNA strategies (138, 139). However, CRISPR/Cas9 KO approaches 
can potentially have off-target effects (140-142). In addition, one group hypothesized that the cells 
may “rewire” their signaling pathways by changing the expression of other genes to compensate 
for the lost transducer (57). Therefore, CRISPR/Cas9 gene KO requires rigorous validation by re-
expressing the deleted genes and rescuing observed deficits to address this potential caveat. Re-
expressing the knocked out gene confirms that the deficit is specific to the knocked out gene and 
not due to any off-target effect or “rewiring” of the cells. 
Tight control of signaling is important for proper neuronal transmission and the ability of 
cells to respond to diverse stimuli. The D1R is no exception to that rule and a multitude of proteins 
tightly regulate the D1R, including -Arr1/2. The D1R recruits -Arr1/2 upon agonist stimulation 
and undergoes endocytosis via clathrin-coated pits (86, 143-145). The D1R is internalized after 
agonist stimulation and is recycled back to the membrane as soon as 20 minutes after agonist 
removal in primary striatal neurons (143). Furthermore, D1R endocytosis occurred in an 
overlapping period to cAMP production and blocking endocytosis attenuated cAMP signaling. 
Interestingly, blocking recycling did not affect cAMP production during these short time courses 
(144). -Arr1/2 recruitment to the D1R, as mentioned before, leads to D1R recruitment to clathrin-
coated pits. Kim el al. used imaging with -Arrestin1-Green fluorescent protein (GFP) and -
Arrestin2-GFP to show that D1R stimulation recruited both -Arr1 and -Arr2 to the membrane 
(24). They continued on to show, that D1R phosphorylation in the third intracellular loop is 
important for -Arr2 recruitment but that the C terminal tail is not essential for -Arr2 recruitment 
(24). These results suggest that D1R phosphorylation may be important for -Arr1/2 recruitment. 
In addition, these studies indicate that both -Arr1/2 are important for D1R signal regulation. 
Several studies have also raised the question of whether clathrin-mediated endocytosis is the 
only endocytosis mechanism for the D1R (146-148) . The D1R co-immunoprecipitated with 
caveolin-1 in COS-7 cells and rat brain extracts. Furthermore, the D1R contains a caveolin binding 
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motif and mutating the motif attenuated D1R caveolin-mediated endocytosis (146). Caveolin-
mediated endocytosis is also dynamin-dependent which aligns with several of the studies above 
that used dynamin dominant negatives or dynamin inhibitors. Together, these studies suggest 
that multiple endocytic pathways may regulate the D1R. However, these studies were not 
conducted in a -Arr1/2 null background and relied primarily on pharmacological inhibitors or 
imaging to investigate D1R endocytosis. Pharmacological inhibitors often have off-target effects 
and imaging may miss smaller effects due to the qualitative and not quantitative nature of the 
experiments. Thus, we decided to revisit the fundamental processes of D1R signaling including 
endocytosis using HEK293 cells with -Arr1/2 knocked out by CRISPR/Cas9. 
These studies show successful KO of -arrestin1/2 (-Arr1/2 KO) from HEK293 cells using 
CRISPR/Cas9 genome editing. First, to investigate the canonical role of -Arr1/2 to arrest G 
protein signaling, D1R agonist-induced increases in cAMP were measured in a live-cell assay 
over a 60-minute time course. Using a unique kinetic assay conducted at 37°C, these studies 
show that -Arr1/2 KO does not influence cAMP during the first 60 minutes of stimulation. Rather, 
the decrease in cAMP during the 60 minutes is partially due to phosphodiesterase activity. The 
kinetic experiments provide valuable insights into cAMP maintenance but the role of -Arr1/2 was 
also determined in classic desensitization paradigms. Desensitization occurs when a cell is 
unable to respond to an agonist after prolonged stimulation. -Arr1/2 KO reduced the ability of 
the D1R to increase cAMP after prolonged agonism indicating impaired D1R desensitization. 
Additionally, -Arr1/2 KO eliminated D1R agonist-induced endocytosis and -Arr1 or -Arr2 re-
expression rescued agonist-induced endocytosis. Finally, the role of -Arr1/2 in agonist-induced 
endocytosis for another neurotransmitter receptor, the 5-HT2A receptor, was determined. The 
role of -Arr1/2 is receptor specific as -Arr1/2 KO did not eliminate 5-HT2A receptor endocytosis; 
however, -Arr1/2 KO did significantly reduce 5-HT2A receptor agonist-induced endocytosis. 
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Together these results indicate that -Arr1/2 are essential for D1R agonist-induced endocytosis 
and that the role of -Arr1/2 is dependent on the specific receptor being studied. 
3.2 Results 
3.2.1 CRISPR/Cas9 knockout of -arrestin1/2 in HEK293 
-Arr1/2 are essential proteins involved in regulating GPCR signaling. To begin with, the 
role of -Arr1/2 in D1R signaling was validated using CRISPR/Cas9 genome editing to KO -
Arr1/2 expression in HEK293. This approach rigorously validates the function of -Arr1/2 in D1R 
signaling without the confounding factors of siRNA strategies (i.e. 20% protein expression 
remaining). We received -Arr1/2 KO and the Parent HEK293 cell lines as a generous gift from 
Dr. Asuka Inoue at the University of Tohoku in Japan. CRISPR/Cas9 genome editing was used 
to first delete ARRB1, the gene for -Arr1. Subsequently, the gene for -Arr2, ARRB2, was 
deleted with CRISPR/Cas9 as described in the methods. Western blotting analysis on three 
clones of -Arr1/2 KO cells confirmed successful KO of -Arr1/2 (Figure 1). Immunoblotting 
demonstrated successful KO of both -Arr1 and -Arr2 in clones 9, 10, and 11, which all had no 
immunoreactivity to either -arr1 or -arr2 antibodies. Western blotting detected -Arr1 and -
Arr2 in the Parent HEK293 cells. Together, these results showed successful KO of both -Arr1 
and -Arr2 in the KO cells. Clone 9 for was used in all subsequent experiments involving the -
Arr1/2 KO cells. 
3.2.2 -arrestin1/2 knockout does not alter cAMP production for 60 minutes following 
agonist stimulation 
 The original role of the arrestin family is to desensitize the receptor to further G protein 









Figure 1. -arrestin1/2 knockout in HEK293 cells using CRISPR/Cas9 genome editing. -
arrestin1 and 2 were sequentially knocked out using CRISPR/Cas9 genome editing generating 
three clonal cell lines. Parent HEK293 and -arrestin1/2 knockout (-Arr1/2 KO) cells were 
analyzed by western blotting as described in methods. A) Western blotting of Parent HEK293 
and -Arr1/2 KO cells demonstrates successful deletion of -arrestin1 (-Arr1) in clone 9, 10, 
and 11. Parent HEK293 cells had immunoreactivity for -Arr1 while Arr1/2 KO clone 9, 10, 
and 11 did not. B) Parent HEK293 cells showed immunoreactivity to -arrestin2 (-Arr2). In -
Arr1/2 KO clones 9, 10, and 11 there was no immunoreactivity for -Arr2 confirming successful 
knockout of -Arr2. Representative blots shown from three independent experiments. Western 
blotting kindly contributed by MK Jain. 
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our laboratory that uses a dynamic live-cell cAMP sensor, Glosensor, to monitor cAMP levels 
over 60 minutes of continuous agonism at saturating concentrations of D1R agonists. The 
kinetic based assay differs from previous assays in that it is performed at 37°C whereas most 
cAMP assays are measured at room temperature. In addition, most cAMP assays are endpoint 
assays and few measure dynamic cAMP levels over time. Here, dynamic cAMP levels were 
measured and followed over a 60-minute period. We hypothesized that -Arr1/2 KO would 
increase the duration of cAMP signaling due to the role of -Arr1/2 in preventing further G 
protein signaling and cAMP production. However, there was no difference observed between 
the Parent HEK293 cells or the -Arr1/2 KO cells (Figure 2A & B). A-77636 treatment sharply 
increased cAMP in both Parent HEK293 and -Arr1/2 KO cells as expected after agonist 
addition. Interestingly, cAMP levels decreased at the same rate in Parent HEK293 and -Arr1/2 
KO cells. Since -Arr1/2 KO did not influence the decay of cAMP levels, a phosphodiesterase 
inhibitor, Isobutyl-methylxanthine (IBMX), was added to the Parent HEK293 cells at the same 
time as agonist treatment. Phosphodiesterases are enzymes responsible for cleaving cAMP and 
helping to restore cAMP levels to basal conditions. IBMX treatment elevated cAMP levels 
indicating that phosphodiesterase activity is partially responsible for the decrease in cAMP 
levels during this 60-minute period (Figure 2A & B). Taken together, these results show that the 
initial decrease in cAMP levels is due to phosphodiesterase activity rather than -Arr1/2.  
3.2.3 -arrestin1/2 knockout reduces D1R cAMP desensitization 
The kinetic experiments above are unique and measure continuous cAMP levels. It is 
unclear by this assay, if re-stimulating the D1R would elicit another wave of G protein signaling 
or if the receptor is desensitized, presumably by -Arr1/2. Thus, classic desensitization 
experiments that stimulate the D1R from 30-240 minutes were performed following which cAMP 








Figure 2.-arrestin1/2 knockout does not alter cAMP kinetics for 60 minutes following 
agonist stimulation but does reduce D1R desensitization. Parent HEK293 and -arrestin1/2 
knockout (-Arr1/2 KO) cells were treated with 10 M A-77636, a full agonist at the D1R. cAMP 
levels were measured at four minute intervals for 60 minutes at 37°C. The kinetic cAMP assay 
measures cAMP levels in live cells at endogenous temperatures over time. In addition, classic 
desensitization experiments were conducted that measure the ability of the cells to produce cAMP 
after prolonged stimulation with A-77636. The differences between the assays is that the kinetic 
assay measures cAMP immediately following agonist addition for 60 minutes while the 
desensitization assay adds the agonist for 30-240 minutes followed by a washout and re-
stimulation with A-77636, at which time cAMP production is measured. A) Both Parent HEK293 
and -Arr1/2 KO cells increase cAMP rapidly in response to 10 M A-77636. cAMP levels then 
decline despite the continued presence of the agonist. We tested a phosphodiesterase inhibitor, 
100 M isobutyl-methylxanthine (IBMX), to determine if phosphodiesterase activity was 
responsible for the decline in cAMP levels. Phosphodiesterase inhibition increased cAMP levels 
but does not fully explain the decreased cAMP levels in Parent HEK293 and -Arr1/2 KO cells. 
B) Area under the curve (AUC) analysis to determine the total cAMP response over the 60-minute 
period indicated -Arr1/2 KO cells were not significantly different from Parent HEK293 cells. 
Parent HEK293 cells treated with IBMX had significantly higher total cAMP levels than Parent 
HEK293. C) -Arr1/2 KO disrupts D1R cAMP desensitization. -Arr1/2 KO cells produced 
significantly more cAMP (less desensitization) after 240 minutes of 10 µM A-77636 compared to 
Parent HEK293 cells. Data presented as Mean ± SEM, n=3, *, p<0.05 vs. Parent HEK293; B) 
One-way ANOVA with Tukey’s multiple comparisons test. C) Two-way ANOVA with Bonferroni’s 
multiple comparisons test. Desensitization kindly contributed by DE Felsing. 
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Parent HEK293 cells, consistent with previously published results obtained in primary neurons 
(86). Further, -Arr1/2 KO significantly reduced D1R desensitization after 240 minutes (Figure 
2C). At earlier time points, 30-120 minutes, -Arr1/2 KO did not significantly alter D1R 
desensitization suggesting that the D1R is a slow desensitizing receptor and that -Arr1/2 has a 
role in classic desensitization of the D1R. Taken together with the cAMP kinetic results, these 
results demonstrate that -Arr1/2 KO does not affect rapid cAMP levels (0-120 minutes); however, 
-Arr1/2 does decrease D1R G protein signaling after sustained stimulation. 
3.2.4 -arrestin1/2 knockout eliminates agonist-induced endocytosis 
 -Arr1/2 also acts as a scaffold for AP-2, a protein adaptor for clathrin, which recruits the 
-Arr1/2-receptor complex to clathrin-coated pits, typically in an agonist-dependent manner (40, 
41). The result is receptor endocytosis that can lead to either receptor recycling back to the 
membrane or receptor degradation and downregulation in the lysosome. Thus, D1R agonist-
induced endocytosis was investigated in the -Arr1/2 KO cells. Using a confocal imaging based 
assay called antibody feeding, the D1R was visualized for agonist-induced endocytosis. Antibody 
feeding is an assay that labels receptors on the membrane of cells using an anti-hemagglutinin 
(HA) Alexa488 conjugated antibody while the cells are chilled on ice to prevent endocytosis. After 
labeling membrane receptors, the cells are warmed to 37°C in the presence of saturating 
concentrations of agonist for 60 minutes before being fixed and imaged. Alexa488 signal inside 
the membrane indicates receptor endocytosis and usually appears a punctate signal. Both Parent 
HEK293 and -Arr1/2 KO Control treated cells had membrane localization for the D1R (Figure 3). 
However, Parent HEK293 cells display agonist-induced D1R endocytosis after treatment with 10 
M SKF-81297 or A-77636 (Figure 3A). In contrast, SKF-81297 or A-77636 treatment did not 
induce D1R endocytosis in the -Arr1/2 KO cells (Figure 3B), suggesting that -Arr1/2 KO blocked 
























Figure 3. -arrestin1/2 knockout eliminates agonist-induced endocytosis. HEK293 and -
arrestin1/2 knockout (-Arr1/2 KO) cells were transfected with 0.25 g HA-D1R. After 48 hours, 
the cell surface D1Rs were labeled with an anti-HA antibody conjugated to Alexa488 on ice to 
prevent endocytosis. The labeled cells were warmed to 37°C in the presence of 1X HBSS with 
20 mM HEPES (Control), 10 M SKF-81297 or 10 M A-77636 for 60 minutes and fixed. The 
coverslips were mounted on slides and imaged by confocal microscopy. A) Treatment with either 
SKF-81297 or A-77636 induced D1R endocytosis in the Parent HEK293 cells while control 
treatment did not induce endocytosis. Punctate and perinuclear staining is visible in SKF-81297 
and A-77636 treated cells. The D1R is largely located at the membrane in untreated Control cells. 
B) Treatment with SKF-81297 or A-77636 did not induced endocytosis in the -Arr1/2 KO. Control, 
SKF-81297, and A-77636 treated cells had membrane localization of the D1R. Images are 
representative of >30 cells from three independent experiments. Scale bar = 10 m. Indicated 
sections are enlarged to show D1R localization. 
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To further investigate the role of -Arr1/2 in D1R agonist-induced endocytosis, D1R 
endocytosis was quantified using the cell surface ELISA. The cell surface ELISA quantifies the 
level of receptor at the membrane of cells using an anti-HA antibody to detect the HA-D1R at the 
membrane under non-permeabilizing conditions. The cells were treated with 10 M A-77636 for 
0-60 minutes as indicated, then fixed. The cell surface ELISA detects the amount of receptor 
remaining at the membrane after the indicated treatment time allowing us to quantify D1R 
endocytosis over time. The data were normalized to untreated cells (time 0, data not shown) and 
presented as percent loss of cell surface HA. Saturating concentrations of A-77636 induced D1R 
endocytosis in the Parent HEK293 cells but not in the -Arr1/2 KO cells (Figure 4). After 60-minute 
treatment with A-77636, 36% of D1R at the membrane was lost in Parent HEK293 cells, indicating 
A-77636 induced D1R endocytosis. In contrast, A-77636 induced less than 10% endocytosis of 
the D1R in the -Arr1/2 KO cells even after 60 minutes of continuous agonism. These results 
provide an orthologous validation of the confocal imaging assay and quantify D1R agonist-
induced endocytosis in the Parent HEK293 and -Arr1/2 KO cells. Together, these studies 
indicate that -Arr1/2 KO eliminates agonist-induced endocytosis of the D1R.  
3.2.5 -arrestin1 and 2 re-expression rescued D1R agonist-induced endocytosis 
 CRISPR/Cas9 genome editing is a powerful strategy that is allowing researchers to re-
investigate the fundamental role of -Arr1/2. Previous siRNA strategies maximally reduce protein 
expression by 80% leaving at least 20% to potentially confound results and interpretations. 
CRISPR/Cas9 genome editing overcomes this problem by deleting the gene; however, 
CRISPR/Cas9 gene editing can also have off-target effects. In addition, one group has claimed 
that CRISPR/Cas9 gene deletion may cause the cells to re-wire, or change gene expression and 
activities of other proteins, to compensate for the lost gene (57).  Thus, -Arr1 and -Arr2 were 






Figure 4. -arrestin1/2 knockout prevents agonist-induced D1R endocytosis. Parent 
HEK293 and -arrestin1/2 knockout (-Arr1/2 KO) cells were transfected with 0.25 g HA-D1R. 
Forty-eight hours later, the cells were treated with 10 M A-77636 for the indicated times then 
fixed. An ELISA assay using an anti-HA antibody was conducted in non-permeabilizing 
conditions. Absorbance measurements were obtained and the data analyzed as described in the 
methods. Treatment with A-77636 induced time dependent D1R endocytosis in the Parent 
HEK293 cells. In contrast, the -Arr1/2 KO cells did not display agonist-induced D1R endocytosis 
over time. At 15, 30, and 60-minute time points, -Arr1/2 KO cells had significantly less 
endocytosis than the Parent HEK293 cells. Data presented as Mean ± SEM, n=3, *, p<0.05 vs. 
Parent HEK293; Two-way ANOVA with Bonferroni’s multiple comparisons test. 
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agonist-induced endocytosis and control of potential off-target effects. Furthermore, using -
Arr1/2 KO cells provides a null background to investigate the role of -Arr1 independent from -
Arr2 and vice versa. First, western blotting analysis was conducted to ensure successful re-
expression of -Arr1 and -Arr2 at comparable levels. -Arr1/2 KO cells were transfected with 
empty vector (EV), -Arr1, or -Arr2 and lysed 48 hours after transfection. Western blotting 
analysis was conducted on the lysates as described in the methods. -Arr1/2 KO cells were not 
immunoreactive to -Arr1 or -Arr2 (Figure 5 A & B, respectively). -Arr1/2 KO cells transfected 
with -Arr1 had immunoreactivity for -Arr1 but not -Arr2. In addition, -Arr1/2 KO cells 
transfected with -Arr2 did not have immunoreactivity for -Arr1 but -Arr2 was detected (Figure 
5). This data indicated successful re-expression of -Arr1 and -Arr2 in the -Arr1/2 KO cells and 
demonstrated relatively equal expression of -Arr1 and -Arr2. 
To validate rigorously that -Arr1/2 KO blocked D1R endocytosis and control for potential 
off-target effects of CRISPR/Cas9 genome editing, -Arr1 and -Arr2 were re-expressed in the -
Arr1/2 KO cells prior to conducting endocytosis imaging. Parent HEK293 and -Arr1/2 KO cells 
were co-transfected with HA-D1R and EV. Control treated Parent HEK293 cells showed 
membrane localization of the D1R whereas A-77636 treated cells had punctate and perinuclear 
signal indicating agonist induce-endocytosis (Figure 6A). -Arr1/2 KO cells had membrane 
localization of the D1R after 60-minute treatment with A-77636 indicating -Arr1/2 KO prevented 
agonist-induced endocytosis (Figure 6A). Next, the HA-D1R and -Arr1 or -Arr2 were re-
expressed in the -Arr1/2 KO cells. Both -Arr1 and -Arr2 rescued D1R agonist-induced 
endocytosis, displaying punctate and perinuclear signal similar to that seen in the agonist treated 
Parent HEK293 cells (Figure 6B). This data indicated that either -Arr1 or -Arr2 are required for 












Figure 5. -arrestin1 and 2 repression in the -arrestin1/2 knockout cells. 0.5 g of -
arrestin1 (-Arr1) or -arrestin2 (-Arr2) was transfected into the -Arrestin1/2 knockout (-
Arr1/2 KO) cells. After 48 hours, the cells were lysed in RIPA buffer and western blotting analysis 
was conducted against -Arr1 and -Arr2 as described in the methods. A) -Arr1 re-expression 
was detected in the -Arr1 transfected cells but not in the -Arr1/2 KO cells or the -Arr2 
transfected cells. B) -Arr2 immunoreactivity was detected in the -Arr2 transfected cells but 
not in the -Arr1/2 KO cells or the -Arr1 transfected cells. Representative blots shown from 





















Figure 6. -arrestin1 or 2 re-expression rescues agonist-induced D1R endocytosis. 
Parent HEK293 and -Arrestin1/2 knockout (-Arr1/2 KO) cells were co-transfected with 0.25 
g HA-D1R and 0.5 g empty vector (EV), 0.5 g -arrestin1 (-Arr1), or 0.5 g -arrestin2 
(-Arr2). Forty-eight hours post-transfection, the cell surface D1Rs were labeled with an anti-
HA Alexa488 conjugated antibody on ice to prevent endocytosis. The cells were warmed to 
37°C in 1X HBSS with 20 mM HEPES (Control) or 10 M A-77636 for 60 minutes and fixed. 
The coverslips were mounted on slides and imaged by confocal microscopy. A) A-77636 
induced D1R endocytosis in the Parent HEK293 cells compared to Control treated Parent 
HEK293 cells. -Arr1/2 KO prevented D1R agonist-induced endocytosis, consistent with 
previous results. B) Re-expressing either -Arr1 or -Arr2 in the -Arr1/2 KO cells rescued 
D1R agonist-induced endocytosis. -Arr1 and -Arr2 transfected cells have punctate and 
perinuclear localization of the D1R similar to the A-77636 treated Parent HEK293 cells. 
Images are representative of >30 cells from three independent experiments. Scale bar = 10 
m. Inset is an enlargement of the indicated area. 
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D1R agonist-induced endocytosis was also quantified using the cell surface ELISA after 
co-transfecting HA-D1R and EV, -Arr1, or -Arr2 into Parent HEK293 and -Arr1/2 KO cells. 
Treatment with A-77636 induced D1R endocytosis in the Parent HEK293 cells with 30% of the 
surface receptors removed from the membrane after 60 minutes (Figure 7). Consistent with the 
previous results, -Arr1/2 KO cells transfected with EV did not undergo agonist-induced D1R 
endocytosis with less than 10% of the surface receptors removed after 60 minutes. -Arr1/2 KO 
cells had significantly less endocytosis after 30 and 60-minute treatment with A-77636 compared 
to Parent HEK293 cells. In contrast, A-77636 induced D1R endocytosis in the -Arr1/2 KO cells 
transfected with either -Arr1 or -Arr2 at comparable level to the Parent HEK293 cells (Figure 
7). These results demonstrate the essential role that -Arr1/2 has in D1R agonist-induced 
endocytosis. Furthermore, these results validated that -Arr1/2 are required for D1R agonist-
induced endocytosis and controlled for any potential off-target effects of CRISPR/Cas9 genome 
editing. 
3.2.6 -arrestin1/2 knockout reduced agonist-induced endocytosis for the 5-HT2A 
To further investigate the role of -Arr1/2 in GPCR agonist-induced endocytosis, another 
neurotransmitter binding GPCR, the serotonin or 5-hydroxytryptamine (5-HT) 5-HT2A receptor, 
was investigated in the -Arr1/2 KO cells. The 5-HT2A receptor was chosen because there are 
reports that the 5-HT2A receptor undergoes both agonist-induced clathrin-mediated endocytosis 
and caveolin-mediated endocytosis, although this may be a cell-type specific phenomenon (149-
151). Interestingly, in HEK293 cells, endocytosis inhibitors, a truncated -Arr2 mutant and a 
dynamin dominant negative did not influence 5-HT2A receptor desensitization in contrast to the 
2-adrenergic receptor (151). When measuring endocytosis specifically, the same group found 
that agonist and antagonist induced endocytosis was dynamin dependent and -Arr1/2 





Figure 7. Re-expressing -arrestin1 or 2 rescues D1R agonist-induced endocytosis. 
Parent HEK293 and -Arrestin1/2 knockout (-Arr1/2 KO) cells were co-transfected with 0.25 
g HA-D1R and 0.5 g empty vector (EV), 0.5 g -arrestin1 (-Arr1), or 0.5 g -arrestin2 (-
Arr2). After 48 hours, the cells were treated with 10 M A-77636 for 0-60 minutes as indicated 
then fixed. An ELISA was conducted in non-permeabilizing conditions to measure the D1R 
remaining at the cell membrane as described in the methods. Parent HEK293 cells underwent 
agonist-induced D1R endocytosis. The -Arr1/2 KO cells had significantly less agonist-induced 
D1R endocytosis, consistent with previous results. Re-expressing either -Arr1 or -Arr2 
rescued D1R agonist-induced endocytosis. Data presented as Mean ± SEM, n=4, *, p<0.05 vs. 




eliminated agonist-induced endocytosis suggesting that the D1R exclusively employs clathrin-
mediated endocytosis for agonist-induced endocytosis. Thus, we decided to investigate 5-HT2A 
receptor endocytosis using the -Arr1/2 KO cells. 5-HT2A receptor endocytosis was quantified 
using the cell surface ELISA in the Parent HEK293 and -Arr1/2 KO cells after treatment with the 
agonists, 5-HT or 2,5-dimethoxy-4-iodoamphetamine (DOI). 5-HT and DOI rapidly and robustly 
induced 5-HT2A receptor endocytosis in the Parent HEK293 cells (Figure 8A & C). Parent 
HEK293 cells endocytosed 52% and 40% of membrane 5-HT2A receptors after 60-minute 
treatments with 5-HT (Figure 8A) and DOI (Figure 8C), respectively. -Arr1/2 KO attenuated 5-
HT2A receptor endocytosis but did not fully prevent endocytosis with 29% and 22% of the receptor 
removed from the membrane after 60-minute treatments with 5-HT (Figure 8A) and DOI (Figure 
8C), respectively. -Arr1/2 KO cells had significantly less endocytosis after just 3-minute 
treatment with 5-HT (Figure 8A) and after 10-minute treatment with DOI (Figure 8C). Total 
endocytosis was quantified using area under the curve (AUC) analysis. -Arr1/2 KO significantly 
reduced 5-HT2A receptor endocytosis over the 60-minute period for both 5-HT (Figure 8B) and 
DOI (Figure 8D). These results suggest that -Arr1/2 has a role in 5-HT2A receptor endocytosis 
but there are also other mechanisms involved and may explain some of the conflicting reports on 
the role of -Arr1/2 in 5-HT2A receptor endocytosis. 
3.3 Discussion 
 Here, the -Arr1/2 KO cells were used to re-investigate the fundamental role of -Arr1/2 
in receptor endocytosis for the D1R and 5-HT2A receptors. First, -Arr1/2 KO did not influence 
cAMP levels following continued agonist stimulation in a unique kinetic assay. However, a classic 
desensitization assay indicated that the -Arr1/2 KO cells had impaired desensitization after 240-
minute treatment with agonist. Moving forward, these results demonstrate that -Arr1/2 are 














Figure 8. Agonist-induced endocytosis of the 5-HT2A receptor is partially dependent 
on -arrestin1/2. Parent HEK293 and -arrestin1/2 knockout (-arr1/2 KO) cells were 
transfected with 0.25 g HA-5-HT2A receptor. Forty-eight hours after transfection, the cells 
were treated with 10 M serotonin (5-HT) or 2,5-dimethoxy-4-iodoamphetamine (DOI) for 0-
60 minutes. An ELISA was conducted with non-permeabilizing conditions to measure the 
receptor remaining at the membrane after treatment. A) 5-HT induced rapid endocytosis in 
the Parent HEK293 and -arr1/2 KO cells. However, Parent HEK293 cells had significantly 
higher levels of endocytosis than the -arr1/2 KO cells at 3, 5, 10, 15, 30, and 60 minutes 
suggesting -arr1/2 plays a role in agonist-induced endocytosis but there may be other 
endocytosis mechanisms involved as well. B) Total endocytosis was measured using area 
under the curve (AUC) analysis. -arr1/2 KO cells had significantly less total receptor 
endocytosis than Parent HEK293 cells. C) DOI, a partial agonist at the 5-HT2A receptor, 
induced rapid endocytosis in the Parent HEK293 and -arr1/2 KO cells. Again, the Parent 
HEK293 cells had significantly higher endocytosis than the -arr1/2 KO at 10, 15, 30, and 
60 minutes. D) -arr1/2 KO cells had significantly less total 5-HT2A receptor endocytosis 
compared the Parent HEK293. Data presented as Mean ± SEM, n=3, *, p<0.05 vs. Parent 




agonist-induced endocytosis. Interestingly, -Arr1/2 KO attenuated 5-HT2A receptor agonist-
induced endocytosis but did not block it to the same extent as the D1R. Together, these results 
support the role of -Arr1/2 in D1R agonist-induced endocytosis and indicate that -Arr1/2 are 
essential for D1R signaling. Furthermore, these results highlight the complexity of GPCR 
transducer interactions and show that -Arr1/2 may have different functions in different receptors. 
 Historically, GPCR signaling and the function of the many protein involved was determined 
by pharmacological and genetic strategies (55-57, 149, 151-154). Pharmacological inhibitors 
often lack specificity and can have off-target effects whereas genetic strategies such as siRNA or 
dominant negative mutants are incomplete knockdowns. While both are useful tools to determine 
the basic function of protein, interpretation of the results must include the caveat that functional 
protein was still present during the assays. For example, siRNA knockdown methods are used to 
transiently knockdown the expression of a protein to study its function in GPCR signaling; 
however, siRNA strategies maximally achieve 80% knockdown allowing the remaining protein to 
influence signal transduction (50). With the advancement of genome editing techniques, it is now 
possible to KO the expression of a specific gene to understand its function in vitro and in vivo (55-
57, 136, 137). CRISPR/Cas9 strategies have confirmed and extended our understanding of the 
function of many genes (139). Genome-editing techniques offer promising strategies to better 
understand GPCR-mediated signal transduction by providing a null background that may aid in 
interpreting results compared to incomplete knockdown with siRNA strategies. 
CRISPR/Cas9 genome editing was used to KO -Arr1/2 providing a null background in 
which to study the function of -Arr1 and -Arr2. After sequentially knocking out -Arr1 and -
Arr2, successful KO of -Arr1/2 was confirmed by western blotting. Next, D1R G protein signaling 
and the role -Arr1/2 have in attenuating G protein signaling was elucidated in the -Arr1/2 KO 
cells in cAMP kinetic assays. We hypothesized that -Arr1/2 KO would increase cAMP levels 
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because -Arr1/2 bind to GPCRs to prevent further G protein activation. Surprisingly, -Arr1/2 KO 
did not influence cAMP production during a 60-mintue kinetic assay conducted at physiological 
temperatures. Instead, phosphodiesterase activity is, at least in part, responsible for the decrease 
in cAMP levels following D1R activation. This unique kinetic assay measures live-cell cAMP levels 
using the Glosensor over 60 minutes following agonist stimulation. It is one of the first cAMP 
assays to measure cAMP at 37°C and follow it for 60 minutes in the same cells. Thus, the kinetic 
assay allows researchers the unique opportunity to investigate the kinetics of G protein signaling 
dynamically in living cells. Interestingly, -Arr1/2 KO reduced D1R cAMP production in 
desensitization assays. D1R cAMP desensitization measures the ability of the D1R to respond to 
repeated and prolonged agonism. The D1R was slow to desensitize reaching only 20% 
desensitization after 60 minutes of exposure to the D1R agonist and -Arr1/2 KO significantly 
reduced desensitization after 240 minutes. This indicates that -Arr1/2 have a role in regulating 
D1R G protein signaling after extended agonism and is consistent with the kinetic experiment in 
which -Arr1/2 KO did not influence cAMP levels during the first 60 minutes of agonist exposure. 
In addition, this study investigated the role of -Arr1/2 in D1R agonist-induced 
endocytosis. -Arr1/2 are adaptors for clathrin-mediated endocytosis and aid in the recruitment 
of the -Arr1/2 bound GPCRs to clathrin coated pits (39, 41). This study demonstrated that -
Arr1/2 are required for D1R agonist-induced endocytosis but less so for the 5-HT2A receptor 
using the -Arr1/2 KO cells. Interestingly, -Arr1/2 have important roles in D1R and 5-HT2A 
receptor agonist-induced endocytosis, but 5-HT2A receptors can also undergo endocytosis in the 
absence of -Arr1/2, albeit, to a lesser extent. Moreover, these results highlight that the function 
of -Arr1/2 is receptor specific and that the CRISPR/Cas9-mediated -Arr1/2 KO cells are a 
powerful tool to re-evaluate the fundamental role of -Arr1/2 using modern techniques.  
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CRISPR/Cas9 genome editing is advancing the understanding of protein function through 
genetic KOs that are superior to siRNA strategies that only knockdown a protein. However, an 
important caveat to CRISPR/Cas9 is the potential for off-target effects (141, 142). To address this 
caveat, -Arr1 or -Arr2 were re-expressed in the CRISPR/Cas9 edited cells. Both -Arr1 and -
Arr2 rescued D1R agonist-induced endocytosis. By re-expressing the -Arr1/2, this study 
rigorously showed that the deficit in agonist-induced D1R endocytosis was specific to the KO of 
-Arr1/2 and not due to an off-target effect. In addition, the -Arr1/2 KO cells allow researchers to 
study the role of -Arr1 independently from -Arr2 and vice versa. Few studies separate the 
function of -Arr1 from -Arr2 and often single out -Arr2 without also investigating -Arr1. For 
example, many groups use -Arr2-GFP constructs to study -Arr2 recruitment to receptors and 
trafficking (86, 155). This study found that -Arr1 and -Arr2 have redundant roles for D1R 
agonist-induced endocytosis. Using the -Arr1/2 KO cells to study -Arr1 and -Arr2 
independently, could help to elucidate receptor specific roles and help to define their specific 
contributions to receptor signaling. For instance, -Arr1 does not activate ERK signaling after 
binding the angiotensin II type 1A receptor whereas -Arr2 binding potentiated ERK signaling 
(37). Furthermore, -Arr2 KO significantly attenuated 2-adrenergic receptor sequestration but -
Arr1 KO did not in mouse embryonic fibroblasts when either -Arr1 or -Arr2 was knocked out 
(38). More studies are needed to determine the specific contributions of -Arr1 and -Arr2 to 
receptor signaling taking into account that each receptor may be regulated differently. These -
Arr1/2 KO cells are powerful tools to help tackle this question easily and efficiently. 
The 5-HT2A receptor does not rely solely on -Arr1/2 for agonist-induced endocytosis. 
The current studies show that -Arr1/2 KO decreases, but does not prevent, 5-HT2A receptor 
agonist-induced endocytosis. As mentioned above, previous studies suggested that 5-HT2A 
receptor agonist-induced endocytosis was dynamin-dependent but -Arr2-independent (151). 
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This study may have missed the effect of the -Arr2 mutant used because qualitative imaging 
was the primary assay used to measure endocytosis. They would still observe receptor 
endocytosis since the 5-HT2A receptor can undergo -Arr1/2 independent endocytosis as well, 
although to a lesser extent according to the present study. Furthermore, they did not consider the 
effect of -Arr1 during the endocytosis imaging experiments (151). A couple years after this study, 
another group discovered that structurally distinct agonists, 5-HT and DOI, elicit distinct patterns 
of receptor endocytosis. In -Arr1/2 KO mouse embryonic fibroblasts, 5-HT did not induce 
endocytosis at 1 M whereas DOI did induce endocytosis (156). This adds another layer of 
complexity to agonist-induced endocytosis that includes cell-type, receptor-specific, and agonist-














4. RESULTS - Balanced and G protein biased non-catechol agonists: characterization and 
consequences on D1R endocytosis 
4.1 Introduction 
The D1R has fundamental roles in the control of voluntary motor movement, working 
memory, attention, and motivation among others. As such, the D1R is a validated drug target with 
the potential to treat cognitive and motor deficits in Parkinson’s disease, cognition in 
schizophrenia, and attention in attention deficit hyperactivity disorder (ADHD) (76, 80-87, 157). 
For more than 40 years, academic and pharmaceutical groups have attempted to develop drug-
like D1R agonists (105, 131, 158). All previous D1R agonists have a common pharmacophore 
known as a catechol. The catechol moiety is associated with poor oral bioavailability, short half-
life, and tolerance, limiting clinical development (84, 118, 157). However, the catechol agonists 
allowed researchers to explore further the therapeutic value of D1R agonists. For instance, 
catechol agonists improve motor deficits associated with Parkinson’s disease models. The 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model produces robust motor and cognitive 
deficits associated with the D1R. Administering catechol agonists relieves motor deficits in non-
human primates previously lesioned with MPTP. However, the researchers also observed 
tolerance or a decline in efficacy in as little as two days with A-77636 or seven days with SKF-
82958 (118).  In addition, catechol agonists improved working memory in human patients with 
schizophrenia. However, the catechol used, dihydrexidine, required intravenous administration 
due to the aforementioned poor oral bioavailability and rapid metabolism (112). Furthermore, 
other proof-of-concept studies conducted in non-human primates show that D1R agonists can 
improve working memory deficits caused by antipsychotic medications, MPTP-lesioning, and 
aging (89, 91). Catechol agonists are useful tools and have greatly advanced our understanding 
of D1R-related behaviors and disorders but lack essential qualities for clinical development. 
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The D1R is a GPCR that couples to the Gs/olf G protein. Agonist binding activates the G 
protein by switching GDP to GTP in the Gs/olf subunit (76). The heterotrimeric G protein 
dissociates into Gs/olf and G subunits that can each interact with downstream proteins to initiate 
signaling cascades. The Gs/olf subunit activates adenylyl cyclase leading to the production of 
cAMP. cAMP is a second messenger that activates signaling cascades resulting in changes in 
neuronal excitability and gene transcription (76). Following G protein activation, -arrestin binds 
the D1R and initiates endocytosis through clathrin-coated pits (24, 86, 143-145). In the previous 
chapter, we demonstrated that D1R agonist-induced endocytosis requires -arrestin. After 
endocytosis, the D1R may be recycled back to the membrane for renewed signaling or possibly 
downregulated by degradation in the lysosome (76, 143).  
Agonists can selectively activate one signaling pathway in favor of another. For instance, 
an agonist could initiate G protein signaling without engaging the -arrestin pathway. This 
selective pathway activation is termed “biased agonism” or sometimes “functional selectivity” (66, 
86, 105, 159-162). G protein and -arrestin pathways can control different physiological 
processes. Selectively targeting one pathway over another allows researchers to fine-tune agonist 
signaling to elicit a particular therapeutic effect with potentially fewer side effects (65, 66, 159, 
163). As such, there is immense effort by academic and pharmaceutical companies to discover 
biased agonists to improve the safety and/or efficacy of drugs (74, 131, 132, 160, 163-165). For 
example, the -opioid receptor is one such receptor with known clinical relevance in analgesia 
but also harmful side effects including respiratory suppression and constipation. Studies in -
arrestin2 knockout mice indicate that opioids such as morphine have prolonged analgesia, 
reduced tolerance, and decreased negative side effects (constipation, respiratory suppression) 
(72, 73). G protein biased opioid receptor agonists reversed morphine tolerance in a mouse 
model (74). Indeed, the degree of G protein bias is suggested to correlate to the safety of the 
opioid (75). G protein biased opioid receptor agonists proceeded into clinical trials where 
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Oliceridine (TRV-130) provided analgesia similar to morphine with reduced respiratory and 
gastrointestinal adverse events. The major limitation for oliceridine is that it must be administered 
intravenously limiting its use to inpatient settings (166, 167). 
In addition, -arrestin biased dopamine D2 receptor agonists provide further support that 
therapeutic efficacy can be separated from side effects. Antipsychotic medications targeting the 
dopamine D2 receptor induce catalepsy, which is an unwanted side effect. The -arrestin biased 
agonist improved antipsychotic action at the dopamine D2 receptor without inducing catalepsy. 
The agonist, UNC9994, in an antagonist for the cAMP pathway but a partial agonist in the -
arrestin pathway. Furthermore, knocking out -arrestin2 in mice eliminated the antipsychotic 
effects of UNC9994 (163). Accumulating evidence indicates biased agonists are therapeutically 
valuable and can fine-tune the effects of medicines to improve their efficacy or reduce side effects. 
L-3,4-dihydroxyphenylalanine (L-DOPA) treatment is the standard of care for Parkinson’s 
disease motor deficits. However, long-term L-DOPA treatment induces dyskinesia. Once L-DOPA 
is taken up by neurons in the substantia nigra, it is converted to dopamine and released during 
synaptic transmission to bind to dopamine receptors including the D1R. Interestingly, -arrestin2 
levels modulate L-DOPA induced dyskinesia. The dyskinetic effects of L-DOPA are exacerbated 
in -arrestin2 knockout mice while overexpressing -arrestin2 reversed dyskinesia (165). This 
study suggests that -arrestin biased D1R agonists may be superior to balanced agonists such 
as dopamine for treating movement deficits in Parkinson’s disease. However, no drug-like -
arrestin biased agonists are currently available to test this hypothesis. In addition, several 
benzazepine D1R agonists exhibit G protein bias. While the benzazepine agonists were 
discovered decades ago, the G protein bias of some of the agonists was not characterized until 
recently. In 2015, David Sibley’s group characterized G protein signaling, -arrestin recruitment, 
and D1R endocytosis for a wide array of D1R agonists including several benzazepine agonists. 
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Interestingly, SKF-38393 and SKF-77434 among others were partial agonists for cAMP 
production but did not engage -arrestin or induce endocytosis (162). Although the results are 
interesting, catechol agonists such as the benzazepine agonists have poor oral bioavailability and 
short serum half-life making in vivo studies difficult. Very recently, the first non-catechol D1R 
agonists were identified at Pfizer, Inc. as part of a drug discovery and development program (86, 
119-122). Of the nearly 3 million compounds screened, only one partial D1R non-catechol agonist 
hit was discovered. This lead to the generation of the first-generation non-catechol agonists 
described in Gray, Allen et al. (2018) (86). Remarkably, all of the first-generation non-catechol 
agonists are G protein biased with partial to full efficacy in increasing cAMP production while also 
exhibiting reduced or absent -arrestin recruitment. Moreover, PF-2334 induced less in vivo 
tachyphylaxis in rodent and non-human primate models (86). The non-catechol agonists are a 
remarkable breakthrough that created the first drug-like selective agonists for the D1R that have 
potential for human clinical testing (105). 
Here, we study several non-catechol D1R agonists and characterize their G protein 
signaling and -arrestin recruitment activities. The downstream effects of balanced and G protein 
biased agonists on D1R agonist-induced endocytosis was also determined. Several non-catechol 
agonists developed at Pfizer and resynthesized in our lab were identified that have good potency 
and efficacy for D1R G protein stimulated cAMP production. Interestingly, many of the non-
catechol agonists did not engage D1R -arrestin recruitment, indicating they are G protein biased 
agonists. However, one non-catechol agonist unexpectedly had excellent G protein and -arrestin 
recruitment efficacy. Two non-catechol agonists are of particular interest, one that is purely G 
protein biased (Cmpd 24) and one that is balanced (Cmpd 19). Furthermore, we tested a subset 
of the agonists for their ability to induce D1R endocytosis. G protein biased agonists do not induce 
endocytosis while balanced agonists do. D1R agonist-induced endocytosis strongly correlated to 
-arrestin recruitment efficacy. Together these studies define the molecular signaling 
59 
 
mechanisms of catechol and non-catechol agonists. Finally, these results demonstrate that G 
protein biased agonists have different effects on downstream receptor endocytosis compared to 
balanced agonists.  
4.2 Results 
4.2.1 Catechol agonist dose-response curves for cAMP and -arrestin recruitment 
 First, previously characterized catechol D1R agonists were tested to a) validate the assays 
for cAMP and -arrestin recruitment in our lab with established agonists and b) to confirm 
previously published research suggesting that some of the benzazepine derivatives are G protein 
biased (162). SKF-81297 was a full agonist for cAMP production but a partial agonist for -arrestin 
recruitment compared to the endogenous agonist dopamine in previous reports (131, 162). Two 
closely related benzazepine derivatives, SKF-38393 and SKF-77434 were G protein biased with 
high partial and partial agonism, respectively in the G protein pathway but no measureable activity 
for -arrestin recruitment in previous studies (162). To replicate these results, dopamine, SKF-
81297, SKF-38393, SKF-77434, and A-77636 were selected for Glosensor and -arrestin 
recruitment assays. All efficacy measurements were normalized to 100% of SKF-81297 because 
the Presto-Tango -arrestin recruitment assay is a gene-reporter based assay that requires long 
incubation times with the agonists. Thus, it was not feasible to use dopamine in the -arrestin 
recruitment assay because it is unstable and becomes rapidly oxidized. Preliminary results with 
dopamine did not saturate in the dose-response curves likely due to this long incubation and rapid 
degradation (data not shown). Consistent with the previous studies, dopamine (Emax = 98%, EC50 
= 38 nM), SKF-81297 (Emax = 100%, EC50 = 3.1 nM) and A-77636 (Emax = 104%, EC50 = 3.1 nM) 
were all potent full agonists for cAMP production. SKF-38393 (Emax = 85%, EC50 = 130 nM) was 
a high partial agonists while SKF-77434 (Emax = 43%, EC50 = 110 nM) as a partial agonist for 




















Figure 9. Dose responses of catechol D1R agonists in cAMP and -arrestin recruitment 
assays. cAMP was measured using the Glosensor assay described in methods. -arrestin 
recruitment was measured using the Presto-Tango assay described in methods. A) Dopamine 
and A-77636 are full agonists at the D1R compared to SKF-81297. SKF-38393 is a high partial 
agonist while SKF-77434 is a partial agonist. A-77636 and SKF-81297 had similar potency while 
all other agonists are rightward shifted. B) Compared to SKF-81297, A-77636 had higher efficacy 
and potency. SKF-38393 and SKF-77434 both had no activity in the -arrestin recruitment assay 
suggesting they are G protein biased agonists. Representative plots shown from at least three 
independent experiments performed in triplicate. Light counts per second (bioluminescence) from 
both assays was normalized to 100% SKF-81297 response. NA = no activity. 
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EC50 = 35 nM) was a super agonist, and can be considered a -arrestin biased agonist compared 
to SKF-81297. SKF-81297 (Emax = 100%, EC50 = 290 nM) was moderately potent in the -arrestin 
recruitment assay. Interestingly, SKF-38393 and SKF-77434 both had no activity in the -arrestin 
recruitment assay (Figure 9B, Table 1). All potency and efficacy measurements are summarized 
in Table 1. These results confirmed that SKF-38393 and SKF-77434 are G protein biased and 
are consistent with previously published studies. Since validating the cAMP and -arrestin assays 
in our lab and confirming that several benzazepines are indeed G protein biased, the novel non-
catechol agonists were characterized next. 
4.2.2 First generation non-catechol agonists are G protein biased 
 As mentioned previously, catechol agonists have poor oral bioavailability, are rapidly 
metabolized, and often induce tolerance in vivo. Thus, to advance D1R agonists into the clinic 
new drug-like agonists are needed to overcome these pitfalls. The first-generation of non-catechol 
agonists were discovered by Pfizer (86, 119-122). An initial screen of nearly three million 
compounds identified one hit compound that was optimized to produce PF-1119, PF-2334, and 
PF-6142 among others. PF-1119 was a partial agonist for cAMP production whereas PF-2334 
and PF-6142 were reported as high partial to full agonists. Interestingly, all three agonists had 
reduced -arrestin recruitment compared to dopamine and SKF-81297 in total internal reflection 
fluorescence (TIRF) microscopy (86). Given that different assays were used to determine -
arrestin recruitment in previous studies (86, 162), it is impossible to compare the ligands directly 
from the published literature. Thus, we set out to compare all ligands together by measuring cAMP 
using the Glosensor cAMP assay and -arrestin recruitment using the Presto-Tango -arrestin 
recruitment assay. In cAMP studies to assess D1R G protein signaling, PF-1119 (Emax = 79%, 
EC50 = 58 nM) and PF-6142 (Emax =91%, EC50 = 22 nM) were high partial agonists compared to 









Figure 10. Dose response curves for the first-generation non-catechol D1R agonists in 
cAMP and -arrestin recruitment assays. Glosensor and Presto-Tango assays were performed 
as described in the methods for cAMP and -arrestin recruitment measurements, respectively. A) 
In the cAMP Glosensor assay, PF-1119, PF-2334, and PF-6142 are all full to high partial agonists 
compared to SKF-81297, an established full agonist at the D1R. The potency was rightward 
shifted by approximately one log unit for PF-1119, PF-2334, and PF-6142 compared to SKF-
81297. B) For -arrestin recruitment, the non-catechol agonists varied from partial agonists to no-
activity in this pathway. PF-2334 was a partial agonist for -arrestin recruitment while PF-6142 
was a very low partial agonist. PF-1119 had no detectable activity for -arrestin recruitment. 
Representative plots shown from at least three independent experiments performed in triplicate. 
Light counts per second (bioluminescence) from both assays was normalized to 100% SKF-












(Figure 10A, Table 1). PF-2334 (EC50 = 490 nM) had the highest efficacy of the first generation 
non-catechol agonists in the -arrestin recruitment assay at 70% of SKF-81297 response. PF-
6142 (EC50 = 245) was a very low partial at 20% of SKF-81297 while PF-1119 had no activity in 
the -arrestin recruitment assay (Figure 10B, Table 1). These results indicate that the first-
generation non-catechol agonists are G protein biased, albeit to varying degrees, and these 
results are consistent with the previous study of these ligands (86). Indeed, PF-1119 was a purely 
G protein biased agonist with no -arrestin recruitment while PF-2334 had higher -arrestin 
activity making it weakly G protein biased. 
4.2.3 Second-generation non-catechol agonists include G protein biased and balanced 
agonists 
 The non-catechol agonists overcame many of the pitfalls associated with catechol 
agonists including poor oral bioavailability, short serum half-life, and tolerance (86, 161). 
However, none of the non-catechol agonists have balanced G protein and -arrestin signaling 
and improvements can always be made to potency. Next, the non-catechol agonist derivatives 
resynthesized within our laboratory (131) and by Martini et al. (132) were characterized. These 
more recent “second-generation” agonists are derivatives of either PF-2334 or PF-6142. To begin 
with, several non-catechol agonists from Martini et al. (132) were analyzed in the Glosensor cAMP 
and -arrestin recruitment assays. Martini et al. (132) derivatized PF-6142, creating 6-(4-
(Furo[3,2-c]pyridin-4-yloxy)-2-methylphenyl)-5-methylpyrazin-2-amine (Cmpd 1), 4-(4-
(Imidazo[1,2-a]pyridin-5-yl)-3-(trifluoromethyl)phenoxy)-furo[3,2-c]pyridine (Cmpd 2), and 7-(4-
(Imidazo[1,2-a]pyridin-5-yl)-3-(trifluoromethyl)phenoxy)-thieno[2,3-c]pyridine (Cmpd 3). Cmpd 1 
(Emax = 92%, EC50 = 470 nM) and Cmpd 3 (Emax = 85%, EC50 = 370 nM) were high partial agonists. 
Of the Martini et al. agonists, Cmpd 2 (EC50 = 180 nM) had the lowest efficacy at 78%, still a high 
partial agonist for cAMP production (Figure 11A, Table 1). These results contrast with Martini et 









Figure 11. Representative dose-response curves for second-generation non-catechol 
agonists from Martini et al. in cAMP and -arrestin recruitment assays. cAMP and -arrestin 
recruitment were measured with the Glosensor and Presto-Tango assays, respectively. Cmpd 1 
and Cmpd 2 were not soluble at high concentrations in the standard 0.1% DMSO used for all the 
other agonists. Cmpd 1 and Cmpd 3 were dissolved in 0.5% DMSO. A) In the cAMP Glosensor 
assay, Cmpd 1 (Emax = 105%, EC50 = 440 nM), Cmpd 2 (Emax = 82%, EC50 = 580 nM), and Cmpd 
3 (Emax = 89%, EC50 = 420 nM) are full to high partial agonists but are also rightward shifted in 
potency by approximately 2 log units compared to SKF-81297. B) Cmpd 1, Cmpd 2, and Cmpd 3 
did not have activity in the -arrestin recruitment assay. Representative plots and data shown 
from at least three independent experiments performed in triplicate. Light counts per second 
(bioluminescence) from both assays was normalized to 100% SKF-81297 response. For Mean ± 
SEM from the three independent experiments, see Table 1. NA = no activity, EC50 = half-maximal 














and 2.2 nM for Cmpd 1, Cmpd 2, and Cmpd 3, respectively. Furthermore, Cmpd 1, Cmpd 2, and 
Cmpd 3 were not active in the -arrestin recruitment assay (Figure 11B, Table 1). For Cmpd 1 
and Cmpd 3, these data are consistent with Martini et al. (132) for previously reported D1R -
arrestin recruitment activity. Cmpd 1 and Cmpd 3 therefore appear G protein biased, which these 
data confirmed. However, Cmpd 2 was a balanced agonist in the Martini et al. (132) paper while 
these results indicate that Cmpd 2 does not have activity in the -arrestin pathway. One potential 
explanation for the discrepancy between the present results and Martini et al. is that -arrestin 
recruitment was measured using different assays, the Tango assay (here) and bioluminescence 
energy transfer assays in Martini et al. However, for all three agonists, the potency was rightward 
shifted in D1R cAMP assays, compared to the previously published study. The decreased potency 
may also explain why Cmpd 1, Cmpd 2, and Cmpd 3 were not active in the -arrestin recruitment 
assay as it is common for -arrestin assays to shift right in potency compared the cAMP assays. 
 Cmpd 19 and Cmpd 24 are also more recently described non-catechol agonists (131). 
Both Cmpd 19 (Emax = 92%, EC50 = 4.4 nM) and Cmpd 24 (Emax = 83%, EC50 = 76 nM) are potent, 
high partial agonists for cAMP production (Figure 12A, Table 1). Interestingly, Cmpd 19 (EC50 = 
100 nM) potently recruited -arrestin with 100% of SKF-81297 response. Cmpd 19 showed an 
unprecedented increase in D1R -arrestin recruitment compared to any of the other non-catechol 
agonists studied. On the other hand, Cmpd 24 had no activity in the -arrestin recruitment assay 
(Figure 12B, Table 1). Together, these results indicate that Cmpd 19 is a full balanced agonist for 
the D1R G protein and -arrestin pathways, while Cmpd 24 is a purely G protein biased agonist. 
4.2.4 G protein biased agonists do not induced D1R endocytosis 
 Agonist-induced D1R endocytosis requires -arrestins, as shown in Chapter 3. Since 
several of the agonists are G protein biased and thus, did not recruit -arrestin, we hypothesized 
























Figure 12. Representative dose-response curves for second-generation non-catechol 
agonists in cAMP and -arrestin recruitment assays. Glosensor and Presto-Tango assays 
were performed as described in the methods for cAMP and -arrestin recruitment measurements, 
respectively. A) Cmpd 19 and Cmpd 24 are both high partial agonists compared to SKF-81297. 
Cmpd 19 has comparable potency to SKF-81297 while Cmpd 24 is less potent than SKF-81297. 
B) In the -arrestin recruitment assay, Cmpd 24 had no activity whereas Cmpd 19 was a full 
agonist. Cmpd 19 exhibited full agonism for cAMP and -arrestin recruitment indicating it is a 
balanced agonist while Cmpd 24 is a G protein biased agonist. Representative plots shown from 
at least three independent experiments performed in triplicate. Light counts per second 




Table 2. EC50 values and Emax for cAMP and -arrestin recruitment of D1R agonists 
 
The values are the Mean ± SEM from at least three independent experiments preformed in 
triplicate. EC50 = half-maximal effective concentration, Emax = maximum effect, nM = nano-molar, 










 cAMP -arrestin recruitment 
Compound EC50 (nM) Emax (% SKF-81297) EC50 (nM) Emax (% SKF-81297) 
SKF-81297 3.1 ± 1 100 ± 2 290 ± 22 100 ± 2 
SKF-77434 110 ± 18 43 ± 2 NA NA 
SKF-38393 130 ± 27 85 ± 1 NA NA 
A-77636 3.1 ± 0.3 104 ± 1 35 ± 4 130 ± 10 
PF-1119 58 ± 10 79 ± 4 NA NA 
PF-2334 11 ± 3 98 ± 3 490 ± 66 70 ± 5 
PF-6142 22 ± 4 91 ± 4 245 ± 55 20 ± 1 
Cmpd 1 470 ± 17 92 ± 7 NA NA 
Cmpd 2 180 ± 32 78 ± 1 NA NA 
Cmpd 3 370 ± 32 85 ± 4 NA NA 
Cmpd 19 4.4 ± 1 92 ± 2 100 ± 28 100 ± 5 
Cmpd 24 76 ± 17 83 ± 1 NA NA 
Dopamine 38 ± 4 98 ± 1 NT  NT  
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of G protein biased agonists on D1R agonist-induced endocytosis, a subset of catechol and non-
catechol agonists were tested in the antibody feeding endocytosis assay. SKF-81297 and 
dopamine are positive control agonists for D1R endocytosis. The results in Chapter 3 
demonstrated that SKF-81297 and A-77636 induced D1R endocytosis. In addition, SKF-81297 
and dopamine recruit -arrestin and induce D1R endocytosis (86, 162). The catechol agonists, 
SKF-81297 and dopamine induced D1R endocytosis in the antibody feeding imaging assay. The 
antibody feeding assay labels cell surface receptors with an Alexa488-labeled antibody. Then, 
the indicated agonist was added and the cells are imaged after 60-minute treatments with the 
agonist. Internalized receptor/antibody appear as punctate signal inside the membrane. The 
vehicle treated cells had primarily membrane D1R without punctate and perinuclear signal (Figure 
13A). SKF-81297 and dopamine induced punctate and perinuclear antibody pattern indicating 
agonist-induced endocytosis (Figure 13 B, C). To further investigate the downstream effects of G 
protein biased agonists on D1R agonist-induced endocytosis, PF-1119, PF-2334, and PF-6142 
were also analyzed in the antibody feeding assay (Figure 13 D, E, & F). The first-generation non-
catechol agonists did not induce substantial D1R endocytosis. Few puncta and no perinuclear 
receptor localization indicated that PF-1119, PF-2334, and PF-6142 did not induce receptor 
endocytosis to the same extent as the balanced catechol agonists SKF-81297 and dopamine. 
Finally, the non-catechol agonists, Cmpd 19 and Cmpd 24, were tested in the antibody feeding 
assay. Cmpd 19 is the only balanced non-catechol agonist and was compared to Cmpd 24, one 
of the pure G protein biased agonists, allowing a comparison between balanced and G protein 
biased non-catechol agonists. Cmpd 19 induced robust D1R endocytosis with punctate and 
perinuclear receptor localization. In contrast, Cmpd 24 did not induce D1R endocytosis with most 
of the receptor remaining at the membrane even after the 60-minute treatment (Figure 13 G & H). 
Together, these results consistently show that G protein biased agonists that do not engage -














Figure 13. G protein biased agonists do not induced endocytosis while balanced agonists 
do. HEK293 cells were transfected with N-terminally HA tagged D1R. The surface D1Rs were 
labeled with an anti-HA antibody conjugated to Alexa488 on ice to prevent endocytosis. The 
indicated agonists were added at saturating concentrations (10 M) and the cells warmed to 37°C 
for 60 minutes, then fixed and imaged as described for Antibody feeding in the methods. A) Cells 
treated with vehicle for 60 minutes do not undergo endocytosis. B, C) Cells treated with the 
catechol agonists, SKF-81297 or dopamine, at saturating concentrations (10M) have punctate 
and perinuclear HA-D1R indicating these balanced, catechol agonists induced endocytosis. D-F) 
In contrast, the non-catechol agonists PF-1119, PF-2334, and PF-6142 did not induce 
endocytosis with very few puncta observed. G) Cmpd 19 is the balanced non-catechol agonist, 
synthesized by our group. Cmpd 19 induced endocytosis similar to the balanced catechol agonists 
with punctate and perinuclear HA-D1R observed in the HEK293 cells. H) Cmpd 24, the pure G 
protein biased non-catechol agonist did not induced endocytosis in HEK293 cells. Representative 
images shown from three independent experiments. Similar results observed in >30 cells. 
Indicated areas enlarged in the lower right corner. 
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To further explore D1R agonist-induced endocytosis, a cell surface ELISA assay was used 
to quantify D1R agonist-induced endocytosis. The imaging results in Figure 13 are compelling 
evidence that G protein biased agonists do not induced endocytosis while balanced agonists do. 
However, to quantify D1R endocytosis over time after treatment with catechol and non-catechol 
agonists a cell surface ELISA assay was used. The cell surface ELISA quantifies the receptor 
remaining at the membrane after treatment. The three catechol agonists, SKF-81297, dopamine, 
and A-77636 all induced D1R endocytosis (Figure 14A). SKF-81297 and dopamine maximally 
induced 33% and 29% loss of cell surface HA, respectively, inducing similar amounts of D1R 
endocytosis (Figure 14A). Whereas A-77636 maximally induced 47% loss of cell surface HA 
(Figure 14A). This is not surprising since A-77636 is also a super agonist in the -arrestin 
recruitment assay compared to SKF-81297. PF-1119 did not induce substantial D1R endocytosis 
with 5% loss of cell surface HA maximally. PF-6142 maximally induced 13% loss of cell surface 
HA while PF-2334 maximally induced 16% loss of cell surface HA (Figure 14B). These results 
align with the -arrestin recruitment results in which PF-1119 did not recruit -arrestin, PF-6142 
was a very low partial agonist, and PF-2334 was a partial agonist. Finally, Cmpd 19 and Cmpd 
24 were also tested in the cell surface ELISA. Cmpd 19 (28% loss of cell surface HA) induced 
similar levels of D1R endocytosis compared to SKF-81297 (33% loss of cell surface HA), which 
is consistent with Cmpd 19 being a balanced agonist (Figure 14C). Cmpd 24, the purely G protein 
biased agonist, maximally induced 11% loss of cell surface HA (Figure 14C). Total D1R 
endocytosis was also quantified using area under the curve (AUC) analysis. A-77636 induced 
significantly more total D1R endocytosis than SKF-81297 while the G protein biased agonists, 
PF-1119, PF-2334, PF-6142, and Cmpd 24 all induced significantly less total D1R endocytosis 
than SKF-81297 (Figure 14D). These results indicate that the balanced agonists induce similar 
amounts of endocytosis while the G protein biased agonists all induced less endocytosis. Further, 










Figure 14. G protein biased agonists do not induce endocytosis while balanced agonists 
induced endocytosis. HEK293 cells transfected with HA-D1R were treated with saturating 
concentrations (10 M) of the indicated agonist for 0-60 minutes and fixed. Anti-HA was used to 
detect HA-D1R remaining at the membrane after treatment under non-permeabilized conditions 
in an ELISA assay as described in the methods. A) Balanced catechol agonists, SKF-81297, 
dopamine, and A-77636 induced endocytosis after agonist treatment. A-77636 induced more 
endocytosis from 10 minutes onward than SKF-81297. SKF-81297 and dopamine induced 
comparable levels of endocytosis. A-77636 treatment reduced cell surface HA-D1R by 47% 
compared to SKF-81297 and dopamine which were 33% and 29%, respectively. B) The first 
generation non-catechol agonists did not induce endocytosis. PF-2334 reduced cell surface HA-
D1R maximally by 16% while PF-1119 induced 5% receptor endocytosis. C) Cmpd 19, the 
balanced non-catechol agonist, induced endocytosis similar to the balanced catechol agonists. 
However, Cmpd 24 did not induce HA-D1R endocytosis with 11% of the receptor undergoing 
endocytosis at the maximum. D) Total D1R endocytosis (Area under the curve, AUC) analysis 
indicated A-77636 induced significantly more D1R endocytosis than SKF-81297. On the other 
hand, PF-1119, PF-2334, PF-6142, and Cmpd 24 induced significantly less total D1R endocytosis 
than SKF-81297. Only dopamine and Cmpd 19 were not significantly different from SKF-81297. 
Data presented as Mean ± SEM, n=3, *, p<0.05 vs. SKF-81297; One (D) or Two-way (A-C) 







more endocytosis than SKF-81297. These results are consistent with the -arrestin recruitment 
assay and the confocal imaging assay. 
These results support the idea that -arrestin recruitment and endocytosis are correlated. To test 
this hypothesis, Spearman’s correlation analysis was conducted between the -arrestin 
recruitment efficacy and D1R endocytosis at 120 minutes. -arrestin recruitment strongly 
correlates with D1R endocytosis (Figure 15, r=0.96, p<0.05). The -arrestin biased agonist, A-
77636 (upper right corner) induced more endocytosis while the G protein biased agonist clustered 
in the lower left corner. Thus, the more an agonist engages -arrestin, the more D1R endocytosis 
the agonist induces. Together, these results support our hypothesis that G protein biased agonists 
do not induce D1R endocytosis while balanced agonist do. 
4.3 Discussion 
To summarize, these results show for the first time, a direct comparison of several catechol 
agonists with non-catechol D1R agonists. These data validated the G protein bias observed with 
some catechol benzazepine agonists (SKF derivatives). Furthermore, these results indicate for 
the first time that A-77636 is a -arrestin biased agonist compared to SKF-81297. In addition, this 
study determined that the non-catechol agonists are commonly G protein biased with one 
unexpected exception, Cmpd 19. Cmpd 1, Cmpd 2, and Cmpd 3 were not as potent for D1R 
cAMP as previously published by Martini et al. (132). In addition, Cmpd 2 was previously reported 
as a balanced agonist but these new results contradict that activity, since Cmpd 2 had no activity 
in the Presto-Tango -arrestin recruitment assay (Figure 11). Due to problems with compound 
solubility and their lack of potency, these three compounds were not tested further. The non-
catechols PF-1119, PF-2334, PF-6142, and Cmpd 24 were all potent full to partial agonists for 
increasing cAMP production but had reduced or absent -arrestin recruitment, indicating that they 










Figure 15.-arrestin recruitment efficacy correlates to D1R agonist-induced 
endocytosis. -arrestin recruitment Emax for each agonist was plotted with the percentage 
of D1R lost after 120-minute treatment with that agonist. Spearmen’s correlation 
coefficient indicated a strong correlation between -arrestin recruitment efficacy and D1R 
endocytosis (r=0.96, p<0.05). 
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tested. Additionally, we tested several of the catechol and non-catechol agonists in D1R 
endocytosis assays. These results indicate that the G protein biased agonists induced less 
endocytosis than their balanced counterparts did. These results strongly indicate that G protein 
bias decreases downstream agonist-induced D1R endocytosis. Taken together, these results 
characterized several non-catechol agonists that are both balanced and G protein biased and 
demonstrate that the degree of G protein bias influences agonist-induced D1R endocytosis. 
To compare more recently synthesized non-catechol derivatives, three promising agonists 
were selected from the Martini et al. (132) report. As mentioned, Cmpd 1, Cmpd 2, and Cmpd 3 
were much less potent than previously described for D1R cAMP activity. Furthermore, Cmpd 2 
was not a balanced agonist and failed to recruit -arrestin. Interestingly, this group followed up 
with a second publication in which they performed further medicinal chemistry and ended up 
validating the balanced D1R signaling activity of Cmpd 19 (Cmpd 10 in their article) (161). Cmpd 
19 is an unprecedented and potent D1R balanced agonist for both D1R G protein and -arrestin 
activity. In addition, Martini et al. extended our studies by showing that Cmpd 19 has good 
pharmacokinetic properties, brain penetrance, and is selective for D1R-like receptors. In the 6-
OHDA unilateral lesion model of Parkinson’s disease, Cmpd 19 also improved motor deficits in 
locomotor and rotation tests. They did not test a G protein biased agonist in these behavioral 
assays (161). The non-catechol agonists that are balanced (e.g. Cmpd 19) or G protein biased, 
are powerful chemical tools to study with in vivo behavioral assays due to their favorable 
pharmacokinetics and diverse signaling (i.e. balanced vs. biased). 
The D1R is a validated drug target for a plethora of neurological disorders and more than 
40 years of research effort focused on developing drug-like agonists. As previously mentioned, 
until very recently all D1R agonists were catechol agonists and suffered from poor oral 
bioavailability, rapid metabolism in the serum, poor brain penetrance, and tolerance (84, 118, 
157). The non-catechol agonists overcome these pitfalls and are excellent candidates to advance 
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into in vivo assays. Most of the non-catechol agonists are G protein biased agonists with only one 
balanced agonist currently (Cmpd 19). Preclinical data suggests that -arrestin biased agonists 
may be better for preventing L-DOPA induced dyskinesia; however, this remains untested as no 
non-catechol -arrestin biased agonist has been reported to date. Increasing -arrestin2 
expression in rats and non-human primates reduced L-DOPA induced dyskinesia. It is worth 
pointing out that L-DOPA increases dopamine and does not specifically target the D1R and other 
mechanisms may also be involved in L-DOPA induced dyskinesia. Further, -arrestin biased 
agonists may not be the best therapeutic route as A-77636 is a -arrestin biased agonist in the 
present studies. A-77636 induces rapid tolerance in rodent and non-human primate model of 
Parkinson’s disease (86). This rapid tolerance is not the same thing as the dyskinesia that 
presents after chronic treatment. Rapid tolerance is nonetheless a pitfall that prevents clinical 
development. A-77636 is a unique agonist in that it is the only -arrestin biased agonist for the 
D1R, to my knowledge, and binds with high affinity, nearly irreversibly, to the D1R. This 
irreversible binding may also play a role in the rapid tolerance and until new -arrestin biased 
agonists are discovered to test this, this question cannot answer this question. 
Currently, the therapeutic potential of balanced and G protein biased agonists can be 
explored further. PF-2334, a G protein biased agonist, induced contralateral rotation in the 6-
OHDA unilateral lesion model in rats. This rotational behavior was significantly higher after three 
days of repeated treatment compared to rats treated with A-77636 treatment. Similar results were 
obtained with the eye-blink rate in non-human primates (86). Eye blink rate is a convenient 
biomarker for D1R activation. These results suggest that G protein biased agonists do not induce 
tolerance as rapidly as catechol agonists such as A-77636. PF-2334 is actually one of the least 
G protein biased non-catechol agonist and it would be interesting to see if the pure G protein 
biased agonists such as PF-1119 or Cmpd 24 do not induce tolerance at all. Moreover, it is 
unknown currently if G protein biased agonists are better than balanced D1R agonists. Our recent 
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profiling of the first balanced non-catechol D1R agonist (Cmpd 19) will allow us to investigate if G 
protein biased or balanced agonism is beneficial in preclinical models. Previously, G protein 
biased agonists had to be compared to catechol agonists that are rapidly metabolized making 
comparisons difficult. Now, it is possible to compare G protein biased non-catechol agonists to 
the balanced non-catechol agonists eliminating the potential confounding factors, 
pharmacokinetics and brain penetrance. Furthermore, the efficacy of G protein biased and 
balanced non-catechol agonists can be tested in a variety of behavioral assays. For example, G 
protein bias may be more beneficial for cognition and working memory while balanced agonists 
may be better for motor disorders. The tools to answer these questions are now available with 
the balanced or biased D1R non-catechol agonists. The non-catechol agonists are a 
breakthrough after 40 years of searching for drug-like D1R agonists. There is great potential for 














5.1 Overall findings and interpretations 
1) Surprisingly, -arrestin does not influence the kinetics of D1R stimulated cAMP for the first 
60 minutes of continuous agonism. Phosphodiesterase activity is partially responsible for 
cAMP decreases during this time period. However, D1R desensitization was reduced in 
-arrestin1/2 knockout cells after four hours indicating -arrestin1/2 still has a role in 
classic D1R/G protein/cAMP desensitization.  
2) These results demonstrate that -arrestin1 or -arrestin2 are required for agonist-induced 
endocytosis. -arrestin1/2 knockout eliminated D1R agonist-induced endocytosis. 
Following these studies, re-expression of -arrestin1 rescued D1R agonist-induced 
endocytosis. Similar results were observed when -arrestin2 was re-expressed in the 
knockout cells. Interestingly, -arrestin1 and -arrestin2 both rescued D1R agonist-
induced endocytosis indicating that they have redundant functions, at least in regards to 
D1R agonist-induced endocytosis. 
3) In addition, G protein/cAMP signaling and b-arrestin recruitment assays were used to 
characterize several catechol and non-catechol agonists. These results confirmed a 
previous report that several benzazepine catechol agonists are G protein biased. One 
catechol agonist, A-77636, appears to be -arrestin biased, a previously overlooked 
characteristic of the agonist. Perhaps more interesting, the non-catechol agonists Cmpd 
19 and Cmpd 24 had superior potency in the G protein pathway compared to other non-
catechol agonists. Importantly, we clarified the activity of several D1R agonists with pure 
G protein bias and the first non-catechol agonist that was balanced was identified in these 
studies. Cmpd 19 is the first non-catechol agonist to exhibit balanced signaling and will be 
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an invaluable tool going forward to compare with the G protein biased non-catechol 
agonists. 
4) To investigate the downstream effects of G protein biased agonists on D1R signaling, we 
investigated the effects of G protein biased agonists on D1R endocytosis. G protein biased 
agonists (that do not recruit -arrestin) do not induce D1R endocytosis. The balanced 
catechol and non-catechol agonists induce D1R endocytosis and the-arrestin biased 
catechol induced greater endocytosis than the balanced agonists. 
 
5.2 Working models of the results 
5.2.1 The role of arrestin in D1R endocytosis 
 The canonical role of -arrestins in GPCR endocytosis is to bind the GPCR after G protein 
activation, desensitizing further G protein signaling and leading to endocytosis of the receptor 
through clathrin-coated pits. The results of these studies support this canonical role of -arrestins 
for the D1R and advance upon previous studies that investigated D1R endocytosis. In the present 
study, -arrestins are absolutely required for D1R agonist-induced endocytosis. Interestingly, the 
reliance of GPCRs on -arrestins for agonist-induced endocytosis appears to be receptor specific 
as 5-HT2A receptor endocytosis is only partly dependent on -arrestins. In this model, the D1R 
binds an agonist leading to G protein activation and increases in cAMP production through 
adenylyl cyclase. -arrestins are then recruited to the D1R preventing further G protein activation 
and leading to receptor desensitization at extended time courses. The D1R/-arrestin complex 
interacts with proteins in clathrin-coated pits and is internalized in an agonist dependent manner. 
Furthermore, this model is now clearly linked to the D1R using a robust genetic knockout model 
and supports previous studies that indicated the D1R is internalized through a dynamin dependent 
process. However, caveolin-mediated endocytosis has also been suggested as an endocytosis 
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mechanism for the D1R. The current study clearly demonstrates that this is not the case for 
HEK293 cells. The major caveat is that caveolin-mediated endocytosis was demonstrated in 
COS-7 cells indicating that caveolin may play a role in other cell types (146). Future studies 
addressing this caveat are outlined below. In addition to endocytosis, caveolin is a protein that 
aids in the formation of lipid rafts/microdomains. The lipid rafts can organize GPCR signaling by 
bringing signaling components (i.e. GPCRs and G proteins) together to promote signaling or 
sequester components to inhibit signaling (168). Thus, caveolin may still be important for the 
regulation of GPCR signaling even if it does not have a role in D1R agonist-induced endocytosis.  
5.2.2 A model for D1R G protein biased agonism 
 Several catechol and non-catechol D1R agonists exhibit G protein biased agonism. G 
protein biased agonism is not a new concept and biased agonists are being pursued for multiple 
GPCRs including the -opioid receptor and the D1R, among others. The idea is that selectively 
targeting one signaling pathway over another may increase the efficacy or reduce on-target side 
effects. Using the D1R as an example, G protein biased agonists may be as effective as 
treatments such as L-DOPA (a dopamine precursor) while also reducing the tolerance associated 
with balanced agonists. The model for the D1R is that a G protein biased agonist activates the G 
protein pathway leading to improved voluntary motor control or improved working memory. The 
G protein biased agonists do not engage the -arrestin pathway preventing D1R endocytosis and 
desensitization. The decreased desensitization could prolong D1R G protein-mediated signaling 
and reduce tolerance. Together with previously reported results, this model provides a potential 
explanation for how the G protein biased agonists improve voluntary movement without inducing 
profound tolerance like previous catechol agonists. A G protein biased non-catechol agonist is 
entering Phase III clinical trials and has excellent safety and tolerability in humans (123, 125, 126, 
169). Further support for this model includes in vivo studies using A-77636. According to the 
present study, A-77636 is a -arrestin biased agonist that robustly induces D1R endocytosis, 
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significantly more than balanced agonists do. A-77636 is associated with rapid and profound 
tolerance even by the second dose 24 hours after the initial dose. Thus, the propensity of an 
agonist to induce tolerance at the D1R may be tied to its ability to recruit -arrestin and induce 
endocytosis. Future studies testing a range of agonists, -arrestin biased to balanced to G protein 
biased, are needed to examine the relation between bias and desensitization/tolerance in vitro 
and in vivo.  
5.3 Significance 
5.3.1 A new mechanism of action for non-catechol D1R agonists 
The non-catechol agonists are a breakthrough simply because they are the first drug-like 
D1R agonists. Interestingly, most of the non-catechol agonists are also G protein biased agonists. 
This study elucidated a new mechanism of action for the G protein biased agonists. The G protein 
biased non-catechol agonists are high partial to full agonists in the G protein pathway indicating 
that they will fully induce the G protein/cAMP/protein kinase A pathway leading to changes in 
protein phosphorylation and gene transcription. However, the novel aspect of their mechanism of 
action is a lack of -arrestin recruitment that leads to decreased receptor endocytosis. The 
obvious implication of a lack of -arrestin recruitment is a lack of receptor desensitization. The 
current studies provide evidence that G protein biased agonists would not induce D1R 
desensitization, since -arrestin1/2 KO reduced D1R cAMP desensitization. This is likely due to 
decreased D1R -arrestin recruitment as well as less D1R endocytosis leaving more D1Rs at the 
membrane to signal. Another interesting implication of the lack of endocytosis is that there is also 
likely less receptor downregulation. As mentioned above, GPCR endocytosis requires the GPCR 
then be sorted into recycling pathways or degradation pathways. The reduced -arrestin 
recruitment and subsequent endocytosis of the G protein biased agonists also suggests that there 
are fewer receptors in the degradation pathways. Thus, the G protein biased non-catechol 
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agonists would likely also have reduced risk of downregulating the D1R receptor. This has great 
potential to increase D1R signaling without inducing drug tolerance. 
Indeed, downregulating the D1R in the brain would produce profound negative 
consequences. A D1R antagonist increased cocaine taking in patients with cocaine use disorder 
and significantly increased depression, anxiety, and suicidal thoughts during a Phase III clinical 
trial of ecopipam for weight loss in obesity (170, 171).  Inhibiting D1R signaling produces profound 
adverse effects. Furthermore, nicotine reduces D1R density in current smokers compared to 
healthy controls in the striatum (172). The authors suggested that the decreased D1R density 
may underlie sustained nicotine use (172).  Cocaine, amphetamine, and methamphetamine all 
decreased dopamine release, the dopamine transporter, and downregulated the D1R in a meta-
analysis that looked at withdrawal after 5 days to 3 weeks (173). The G protein biased non-
catechol D1R agonists have great potential in treating these disorders by normalizing D1R 
signaling without exacerbating the hypodopaminergic state during withdrawal by further 
downregulating the D1R. Specifically, a partial D1R agonist could be used to normalize D1R 
signaling without the potential of producing a “high” since the efficacy is lower than dopamine.  
Moreover, a partial D1R agonist may prevent a “high” if the patient relapses and the partial agonist 
is at high receptor occupancy, preventing the binding of the fully efficacious dopamine. The G 
protein biased non-catechol agonists may be ideal candidates for elevating D1R signaling in these 
individuals. 
5.3.2 Therapeutic implications for balanced and G protein biased agonists 
 The major implications for this research project are the potential therapeutic benefits of 
the identified non-catechol agonists. The non-catechol D1R agonists overcome the pitfalls 
associated with the previous catechol D1R agonists. Catechol agonists are associated with poor 
oral bioavailability, poor serum half-life, and rapid tolerance. The non-catechol agonists overcome 
these pitfalls. Furthermore, Phase I studies indicate the non-catechol agonists are safe and well-
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tolerated in patients with schizophrenia and early-stage Parkinson’s disease (123, 125, 126). 
Cerevel, a small biotechnology spin-off company from Pfizer, is taking the non-catechol agonists 
forward and recently completed Phase II studies (124, 169). The results of a Phase II clinical 
study of early-stage Parkinson’s disease followed patients over 15 weeks and ended with 
favorable outcomes, reducing motor deficits with few adverse reactions. Based on these results 
Cerevel is planning a Phase III clinical trial for early and late-stage Parkinson’s disease beginning 
in 2020 (https://www.cerevel.com/news/cerevel-therapeutics-announces-positive-results-from-a-
phase-2-study-of-tavapadon-in-patients-with-early-stage-parkinsons-disease/) (169).  
Surprisingly, most of the non-catechol agonists are G protein biased agonists. This thesis 
project also characterized the first balanced non-catechol agonist along with a purely G protein 
biased non-catechol agonist. Together these agonists are invaluable tools to study balanced and 
biased D1R signaling in vitro and in the future in vivo (detailed below). Here, we show that the G 
protein biased agonists do not induce D1R endocytosis while the balanced agonists do. Reduced 
or absent -arrestin recruitment and subsequent D1R endocytosis may explain why the G protein 
biased agonists also do not induce the profound tolerance that previous catechol agonists such 
as A-77636 did. PF-2334 induced significantly less tachyphylaxis in a rat model of Parkinson’s 
disease (86). PF-2334 also did produce tachyphylaxis in non-human primates after three days as 
measured by the eye-blink test (a convenient biomarker for D1R engagement) (86). PF-2334 was 
compared to A-77636 in these behavioral studies and interestingly PF-2334 is one of the least G 
protein biased non-catechol agonists. These results suggest that -arrestin biased (A-77636) 
agonists engage more with -arrestin leading to receptor endocytosis and potentially 
downregulating the D1R reducing efficacy in a little as one day. However, the G protein biased 
agonists do not induce endocytosis and likely do not downregulate the D1R leading to sustained 
therapeutic efficacy. As such, the G protein biased non-catechol agonists have the potential to 
alleviate motor deficits in Parkinson’s disease, cognitive deficits in schizophrenia, attention deficits 
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in ADHD, and alter reward processing in substance use disorders. The non-catechol agonists are 
the first D1R drug-like agonists and took 40 years of concerted research effort to create these 
promising, novel agonists. 
5.4 Future directions  
The molecular effects of G protein biased signaling at the D1R is not clearly understood. 
In the present study, only one downstream effect of G protein biased signaling at the D1R was 
examined, endocytosis. This study demonstrated that G protein biased agonists do not induce 
endocytosis. It is logical that agonists that do not recruit -arrestin also do not induce endocytosis 
considering that -arrestins are required for agonist-induced endocytosis of many GPCRs. The 
current studies focused exclusively on the -arrestin recruitment pathway. Future studies 
examining the effect of G protein bias on the G protein pathway are the next logical step to 
advance this research. For example, does less -arrestin recruitment lead to prolonged G protein 
activation and reduced D1R desensitization? Furthermore, investigating downstream signaling 
events such as CREB phosphorylation would provide a more holistic picture of the effects that G 
protein biased agonists have on D1R signaling. We hypothesize that G protein biased agonists 
have prolonged CREB phosphorylation due to decreased D1R desensitization. Another future 
direction is to investigate dopamine D5 receptor (D5R) signaling with the G protein biased 
agonists. Sibley’s group showed that while several benzazepine agonists where G protein biased 
at the D1R, the same benzazepine agonists were balanced at the D5R. Thus, it would be very 
interesting to see if this trend continues with the structurally distinct non-catechol agonists. 
Distinguishing the D1R and D5R pharmacologically has been extremely difficult with most 
agonists having similar effects on both receptors. Furthermore, relatively little, compared to the 
D1R, is known about the D5R and its role in vivo since most previous agonists were grouped into 
the D1R-like category. Finally, while -arrestins are required for D1R agonist-induced endocytosis 
in HEK293 cells, validating these results in other cell types may be beneficial. As mentioned 
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above, caveolin-mediated endocytosis may play a role in D1R endocytosis in COS-7 cells. Thus, 
investigating D1R endocytosis in -arrestin1/2 knockout COS-7 cells may aid in determining if -
arrestins play a universal role in endocytosis or if caveolin may be important depending on the 
cell type. However, it may be more relevant to investigate if -arrestin is essential for D1R 
endocytosis in a neuronal cell type. To achieve this goal, a neuronal cell line such as SH-SY5Y 
or primary striatal neurons could be used. However, the limitation is that neuronal cell lines are 
difficult to transfect and siRNA strategies cannot knockout -arrestin expression. 
Another potential avenue to continue this work is to take the non-catechol agonists into in 
vivo studies. While several G protein biased agonists have entered clinical trials and are showing 
promise for treating Parkinson’s disease, balanced non-catechol agonists have not been defined 
until very recently. Studying the different effects of balanced and biased agonists was incredibly 
difficult previously as the catechol agonists have very poor pharmacokinetics while the non-
catechols have good pharmacokinetics. Thus, studies that compared catechol and non-catechol 
agonists always have a major caveat: Is the observed difference due to differences in 
pharmacokinetics or D1R agonist activity? Both the balanced and G protein biased non-catechol 
agonists exhibit good in vivo pharmacokinetics (86, 161). The G protein biased agonists can aid 
in determining the G protein signaling specific contributions to D1R behaviors. For examples, it 
appears that voluntary movement is primarily initiated through the G protein pathway due to the 
efficacy of the G protein biased non-catechol agonists. However, other D1R behaviors such as 
attention, reward processing, and motivation have not been evaluated using the G protein biased 
and balanced agonists. Pathway specific contributions to signaling is an exciting new area of 
research for the non-catechol D1R agonists. In addition, it is not currently known if G protein 
biased agonists are actually better than balanced agonists. While it is hypothesized that G protein 
biased agonists will be superior to balanced agonists due to decreased tolerance and in vivo 
tachyphylaxis, this has not been directly tested in animal models. Researchers now have the 
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appropriate tools to answer this question. The balanced and G protein biased non-catechol 
agonists would ideally be compared across an array of behaviors and disease models to 
determine if G protein biased agonists are indeed, therapeutically superior to balanced agonists. 
For instance, the balanced and G protein biased agonists should be tested in Parkinson’s disease 
models such as the 6-OHDA unilateral lesion model and cognitive deficit models such as 
ketamine-induced working memory deficits. These studies should be designed to include 
measures of efficacy (increased rotational behavior, improved working memory) and also test the 
potential for tolerance after repeated and chronic dosing. Carefully designing these in vivo studies 
will answer the question of whether G protein biased agonists are therapeutically superior to 
balanced agonists.  
Additional clinical trials are also needed to further test the therapeutic benefit of the G 
protein biased non-catechol agonists in diseases other than Parkinson’s. As mentioned above, 
the D1R has fundamental roles in cognition including working memory and attention as well as 
reward processing and mood. The major focus of clinical trials has been on Parkinson’s disease, 
which is of course an important target for D1R agonists. In addition, there was a Phase Ib study 
conducted in patients with stable schizophrenia, but no cognitive or reward processing effects 
were observed, likely due to limitations of the study design being geared towards safety and 
tolerability. Repurposing the non-catechol agonists for diseases other than Parkinson’s disease 
requires further clinical trials, but the non-catechol agonists may alleviate symptoms currently 
untreatable such as deficits in working memory in patients with schizophrenia. 
5.5 Conclusions 
 The non-catechol agonists are an incredible advancement after 40 years of research 
targeting the D1R. Furthermore, these results highlight a novel mechanism of action for non-
catechol D1R agonists that are G protein biased in which there is normal G protein signaling but 
the agonists do not induce receptor endocytosis. Additionally, the research contained in this thesis 
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demonstrates an essential role for -arrestins in D1R agonist-induced endocytosis. We 
characterized catechol and non-catechol agonists showing novel -arrestin biased signaling for 
one catechol agonist and identifying promising balanced and G protein biased non-catechol 
agonists. Interestingly, the G protein biased non-catechol agonists do not induce endocytosis 
while balanced agonists do. Together these studies provide a logical progression from -arrestins 
role in agonist-induced endocytosis through the lack of endocytosis observed with the G protein 
biased agonists. It is logical that G protein biased agonists do not induce endocytosis when they 
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